var title_f8_54_9056="Intercostal neurofibroma CT";
var content_f8_54_9056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intercostal nerve neurofibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pleural/extrapleural mass in the right hemithorax (arrow). CT shows homogeneous soft tissue attenuation of this mass which originates from the intercostal space structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9056=[""].join("\n");
var outline_f8_54_9056=null;
var title_f8_54_9057="Contents: Pregnancy complications";
var content_f8_54_9057=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pregnancy complications",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pregnancy complications",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Amniotic fluid disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14233\">",
"           Oligohydramnios",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/44/4808\">",
"           Polyhydramnios",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/22/20840\">",
"           Management of cardiopulmonary arrest in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24202\">",
"           Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/54/4968\">",
"           Prenatal sonographic diagnosis of fetal cardiac anomalies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36902\">",
"           Amniotic band sequence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/0/23562\">",
"           Congenital cytogenetic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28026\">",
"           Congenital diaphragmatic hernia in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42169\">",
"           Congenital diaphragmatic hernia: Prenatal diagnosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/165\">",
"           Diagnosis and management of twin reversed arterial perfusion (TRAP) sequence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/44/20169\">",
"           Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/39/12920\">",
"           Fetal ventriculomegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7386\">",
"           Genetic and environmental causes of birth defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/21/6488\">",
"           Obstetrical and neonatal management of body stalk anomalies and cloacal abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/40/35464\">",
"           Obstetrical management of gastroschisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38454\">",
"           Obstetrical management of omphalocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/44/32456\">",
"           Overview of echogenic masses and calcification in the fetal abdomen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23431\">",
"           Preimplantation genetic diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37623\">",
"           Preimplantation genetic screening (PGS) for aneuploidy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/42/10919\">",
"           Prenatal diagnosis and management of bronchopulmonary sequestration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11561\">",
"           Prenatal diagnosis and management of congenital pulmonary airway malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2762\">",
"           Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12500\">",
"           Prenatal diagnosis of congenital mesoblastic nephroma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/62/34793\">",
"           Prenatal diagnosis of gastrointestinal atresia and obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/23/33141\">",
"           Prenatal diagnosis of talipes equinovarus (clubfoot)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42585\">",
"           Prenatal diagnosis of the lethal skeletal dysplasias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15737\">",
"           Prenatal sonographic diagnosis of cystic renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34247\">",
"           Prenatal sonographic diagnosis of fetal abdominal wall defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/54/4968\">",
"           Prenatal sonographic diagnosis of fetal cardiac anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/7/19574\">",
"           Principles of teratology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/46/35560\">",
"           Ultrasound diagnosis of neural tube defects",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/39/4725\">",
"           Cushing's syndrome in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37866\">",
"           Medical management and follow-up of gestational diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9210\">",
"           Screening and diagnosis of diabetes mellitus during pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal growth restriction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22906\">",
"           Diagnosis of fetal growth restriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23994\">",
"           Fetal growth restriction: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/63/13302\">",
"           Interpregnancy interval and pregnancy outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10616\">",
"           Overview of causes of and risk factors for fetal growth restriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/35/22068\">",
"           Postnatal assessment of gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/23/9593\">",
"           Small for gestational age infant",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/9/1178\">",
"           Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38999\">",
"           Counseling parents after stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/6/8298\">",
"           Definition and etiology of recurrent pregnancy loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/35/1591\">",
"           Diagnosis and management of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/3/26679\">",
"           Evaluation of couples with recurrent pregnancy loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38839\">",
"           Evaluation of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31306\">",
"           Incidence, etiology, and prevention of stillbirth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21752\">",
"           Incidence, risk factors, and pathology of ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/49/27417\">",
"           Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/23/19834\">",
"           Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/53/5976\">",
"           Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/24/34184\">",
"           Ultrasonography of pregnancy of unknown location",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36819\">",
"           Intrauterine fetal transfusion of platelets",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13210\">",
"           Intrauterine fetal transfusion of red blood cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/21/5464\">",
"           Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32982\">",
"           Overview of Rhesus (Rh) alloimmunization in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/60/12232\">",
"           Prenatal management of neonatal alloimmune thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40648\">",
"           Prevention of Rh(D) alloimmunization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/27/3513\">",
"           Significance of minor red blood cell antibodies during pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8311\">",
"           Clinical features and diagnosis of placenta accreta, increta, and percreta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/13/35032\">",
"           Clinical features, diagnosis, and course of placenta previa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/45/3800\">",
"           Diagnosis and management of massive fetomaternal hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/16/19719\">",
"           Management of placenta accreta, increta, and percreta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/60/42952\">",
"           Management of placenta previa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/38/42600\">",
"           Overview of postpartum hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15465\">",
"           Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29367\">",
"           Peripartum hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/46/29417\">",
"           Placental abruption: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/54/34663\">",
"           Placental abruption: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/18/20775\">",
"           Velamentous umbilical cord insertion and vasa previa",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperemesis gravidarum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41207\">",
"           Clinical features and evaluation of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/20/29002\">",
"           Treatment and outcome of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/33001\">",
"           Genital herpes simplex virus infection and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28041\">",
"           Overview of TORCH infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40408\">",
"           Parvovirus B19 infection during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/63/4089\">",
"           Placental infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6087\">",
"           Rubella in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4057\">",
"           Syphilis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/39/22137\">",
"           Toxoplasmosis and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33225\">",
"           Varicella-zoster virus infection in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Liver disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/38/24166\">",
"           Acute fatty liver of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/37/26198\">",
"           Approach to liver disease occurring during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41207\">",
"           Clinical features and evaluation of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17897\">",
"           HELLP syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4617\">",
"           Intrahepatic cholestasis of pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malpresentation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/43/21176\">",
"           Delivery of the fetus in breech presentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/5/8281\">",
"           External cephalic version",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/8/13448\">",
"           Overview of breech presentation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple gestation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5510\">",
"           Delayed-interval delivery in multifetal pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9913\">",
"           Management of twin-twin transfusion syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/31/43511\">",
"           Monoamniotic twin pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27594\">",
"           Neonatal outcome, complications, and management of multiple births",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28039\">",
"           Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/28/11718\">",
"           Triplet pregnancy: Early pregnancy management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12842\">",
"           Triplet pregnancy: Mid and late pregnancy complications and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40682\">",
"           Twin pregnancy: Prenatal issues",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/53/21334\">",
"           Incarcerated gravid uterus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/58/9128\">",
"           Inter-facility maternal transport",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/37/34393\">",
"           Nonimmune hydrops fetalis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/45/15065\">",
"           Pregnancy in women with uterine leiomyomas (fibroids)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/4/44102\">",
"           Rupture of the unscarred uterus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postterm birth",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/9/16535\">",
"           Postterm pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preeclampsia and eclampsia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17832\">",
"           Abnormalities of coagulation and platelet function in preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/2/32808\">",
"           Expectant management of severe preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29383\">",
"           Gestational hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17897\">",
"           HELLP syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/61/34777\">",
"           Pathogenesis of preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11480\">",
"           Prediction of preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27978\">",
"           Preeclampsia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21882\">",
"           Preeclampsia: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41609\">",
"           Prevention of preeclampsia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Premature rupture of membranes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4407\">",
"           Management of premature rupture of the fetal membranes at term",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27353\">",
"           Midtrimester preterm premature rupture of membranes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32393\">",
"           Pathogenesis of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15866\">",
"           Preterm premature rupture of membranes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preterm birth",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/55/31610\">",
"           Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4457\">",
"           Cervical insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/51/15159\">",
"           Fetal fibronectin for prediction of preterm labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35674\">",
"           Inhibition of acute preterm labor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/63/13302\">",
"           Interpregnancy interval and pregnancy outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42761\">",
"           Intraamniotic infection (chorioamnionitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/36/24135\">",
"           Management of pregnant women after inhibition of acute preterm labor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27353\">",
"           Midtrimester preterm premature rupture of membranes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5608\">",
"           Overview of preterm labor and birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32393\">",
"           Pathogenesis of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/0/6153\">",
"           Physiology of parturition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/6/2154\">",
"           Pregnancy outcome after assisted reproductive technology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/31/15866\">",
"           Preterm premature rupture of membranes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11994\">",
"           Prevention of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/33/5657\">",
"           Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/3/35898\">",
"           Risk factors for preterm labor and delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/49/32532\">",
"           Transabdominal cervical cerclage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37544\">",
"           Transvaginal cervical cerclage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/33/21017\">",
"           Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33479\">",
"           Acute kidney injury (acute renal failure) in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgical disease and trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8727\">",
"           Laparoscopic surgery in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15482\">",
"           Management of pregnant women undergoing nonobstetric surgery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29657\">",
"           Dermatoses of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44041\">",
"           Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/2/41000\">",
"           Obstetrical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22569\">",
"           Trauma in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E46AC69CC6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_54_9057=[""].join("\n");
var outline_f8_54_9057=null;
var title_f8_54_9058="Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes";
var content_f8_54_9058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9058/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9058/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9058/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/54/9058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 57-year-old woman was found to have hyperglycemia at a health fair when a random blood glucose level was 227",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (12.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Several days later a fasting blood glucose value was 147",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    She has no previous history of diabetes, is alarmed by the possibility of having this disorder, and seeks your advice.",
"   </p>",
"   <p>",
"    The patient has been treated for hypertension for 10 years, currently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    10 mg by mouth daily. She was once told that her cholesterol value was \"borderline high,\" but does not know the value.",
"   </p>",
"   <p>",
"    She denies symptoms of diabetes, chest pain, shortness of breath, heart disease, stroke or circulatory problems of the lower extremities.",
"   </p>",
"   <p>",
"    She estimates her current weight at 165 lbs (75 kg). She thinks she weighed 120 lbs (54 kg) at age 21 years, but gained weight with each of her three pregnancies, and did not return to her non-pregnant weight after each delivery. She weighed 155 lbs one year ago, but gained weight following retirement from her job as an elementary school teacher. No family medical history is available because she was adopted. She does not eat breakfast, has a modest lunch and consumes most of her calories at supper and in the evening.",
"   </p>",
"   <p>",
"    On examination, blood pressure is",
"    <span class=\"nowrap\">",
"     140/85",
"    </span>",
"    supine and",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    upright with a regular heart rate of",
"    <span class=\"nowrap\">",
"     76/minute.",
"    </span>",
"    She weighs 169 lbs, with a BMI of 30.9",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    Fundoscopic examination reveals no evidence of retinopathy. Vibratory sensation is absent at the great toes, reduced at the medial malleoli and normal at the tibial tubercles. Light touch sensation is reduced in the feet, but intact more proximally. Knee jerks are 2 + bilaterally, but the ankle jerks are absent. The exam is otherwise within normal limits.",
"   </p>",
"   <p>",
"    Fasting laboratory studies are as follows: glucose 141",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    sodium 143, potassium 4.1, chloride 103, and carbon dioxide 25",
"    <span class=\"nowrap\">",
"     meq/L;",
"    </span>",
"    triglycerides 210",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    total cholesterol 222",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    HDL cholesterol 73",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and LDL cholesterol 107",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    A1C 8.4 percent. The urine",
"    <span class=\"nowrap\">",
"     microalbumin/creatinine",
"    </span>",
"    ratio is 14.3",
"    <span class=\"nowrap\">",
"     mg/g.",
"    </span>",
"   </p>",
"   <p>",
"    You conclude that the patient has type 2 diabetes, recently diagnosed. You suspect that the patient has had diabetes for a prolonged period because of evidence of distal sensory neuropathy on exam. Because of the elevated blood pressure values, you begin",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    5 mg daily and plan to stop the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    when the blood pressure is in satisfactory control. You note the lipid values and plan to reassess them when the patient's diabetes is in satisfactory control.",
"   </p>",
"   <p>",
"    You counsel the patient about changes in lifestyle. You discuss medical nutrition therapy with the patient with the goal of preventing further weight gain and achieving modest weight reduction. You advise her to eat three meals a day including breakfast, to control the size of portions, to reduce the evening snacks, and to limit her intake of fat. You refer her to a nutritionist for individualized counseling about medical nutrition therapy and to a certified diabetes educator for teaching about diabetes. You also advise the patient to begin a regular program of exercise, and she agrees to walk for 30 to 35 minutes a day at least five times a week.",
"   </p>",
"   <p>",
"    What medication would you prescribe for the management of the patient's diabetes?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      None. You wish to assess the effects of a trial of lifestyle change including medical nutrition therapy and exercise before adding medication. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a1?source=see_link\">",
"       \"Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      500 mg twice a day with breakfast and supper. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a2?source=see_link\">",
"       \"Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       Glyburide",
"      </a>",
"      2.5 mg once a day in the morning. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a3?source=see_link\">",
"       \"Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A3\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       Pioglitazone",
"      </a>",
"      15 mg once a day in the morning. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a4?source=see_link\">",
"       \"Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A4\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"       Sitagliptin",
"      </a>",
"      100 mg once a day in the morning. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a5?source=see_link\">",
"       \"Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A5\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4207 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9058=[""].join("\n");
var outline_f8_54_9058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a1?source=related_link\">",
"      Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a2?source=related_link\">",
"      Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a3?source=related_link\">",
"      Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a4?source=related_link\">",
"      Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?8/54/9058-a5?source=related_link\">",
"      Interactive diabetes case 17: A 57-year-old woman with newly discovered type 2 diabetes-A5",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_54_9059="Hexachlorophene: Pediatric drug information";
var content_f8_54_9059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hexachlorophene: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=see_link\">",
"    see \"Hexachlorophene: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/41/28307?source=see_link\">",
"    see \"Hexachlorophene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      pHisoHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      pHisoHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibacterial, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Soap",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=see_link\">",
"      see \"Hexachlorophene: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical: Apply 5 mL cleanser and water to area to be cleansed; lather and rinse thoroughly under running water; for use as a surgical scrub, a second application of 5 mL cleanser should be made and the hands and forearms scrubbed for an additional 3 minutes, rinsed thoroughly with running water and dried",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     pHisoHex&reg;: 3% (150 mL, 480 mL, 3840 mL [DSC]) [contains sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only; rinse thoroughly after each use",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3071517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with many metals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in nonmetallic container (incompatible with many metals); protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Surgical scrub and as a bacteriostatic skin cleanser; to control an outbreak of gram-positive staphylococcal infection when other infection control procedures have been unsuccessful",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       pHisoHex&reg; may be confused with Fostex&reg;, pHisoDerm&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS injury, irritability, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, dry skin, photosensitivity, redness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to halogenated phenol derivatives or hexachlorophene; use in premature infants; use on burned or denuded skin; use with an occlusive dressing; application to mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Do not use for bathing infants; do not apply to mucous membranes; premature and low birth weight infants are particularly susceptible to hexachlorophene topical absorption; irritability, generalized clonic muscular contractions, decerebrate rigidity, and brain lesions in the white matter have occurred in infants following topical use of 6% hexachlorophene; exposure of preterm infants or patients with extensive burns has been associated with apnea, convulsions, agitation, and coma",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13892598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Hexachlorophene is absorbed systemically when applied topically. Following use as an antiseptic for vaginal exams during labor, hexachlorophene is detectable in the maternal serum and cord blood (Strickland, 1983). Vaginal use as a pack or tampon and application to mucous membranes is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bacteriostatic polychlorinated biphenol which inhibits membrane-bound enzymes and disrupts the cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Percutaneously through inflamed, excoriated and intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, infants: 6.1-44.2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/41/28307?source=see_link\">",
"      see \"Hexachlorophene: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid prolonged contact with skin. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lester RS, &ldquo;Topical Formulary for the Pediatrician,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(4):749-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/54/9059/abstract-text/6225068 /pubmed\" id=\"6225068 \" target=\"_blank\">",
"        6225068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13351 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9059=[""].join("\n");
var outline_f8_54_9059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179113\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179114\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047672\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047666\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179103\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179088\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047675\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3071517\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047669\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047674\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179129\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179128\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047678\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047665\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299444\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179097\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179099\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892598\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047664\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047677\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047671\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=related_link\">",
"      Hexachlorophene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/41/28307?source=related_link\">",
"      Hexachlorophene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_54_9060="Type 2 breast lobule";
var content_f8_54_9060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Type 2 breast lobule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whole mount preparation of breast tissue of a 24-year-old nulliparous woman showing type 2 breast lobules&nbsp;as viewed by&nbsp;light microscopy.",
"    <br>",
"     <br>",
"      Left panel: Tissue section stained with toluidine blue. X 2.5. Right panels: histological section of lobule type 2 stained with hematoxylin and eosin (H &amp;E). Photographs at 10x and 40x respectively.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Russo, J, Hu, Y-F, Silva, IDCG, and Russo, IH. Cancer risk related to mammary gland structure and development. Microscopy Research and Technique 2001; 52:204. Copyright &copy; 2001 American Cancer Society.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9060=[""].join("\n");
var outline_f8_54_9060=null;
var title_f8_54_9061="Hormone levels in HF";
var content_f8_54_9061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58128%7ENEPH%2F55554%7ECARD%2F59265%7ECARD%2F78693%7ECARD%2F58488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58128%7ENEPH%2F55554%7ECARD%2F59265%7ECARD%2F78693%7ECARD%2F58488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Hormone levels in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 223px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plasma levels of norepinephrine, renin activity, and antidiuretic hormone are increased two to eightfold (when compared to normal subjects) in patients with stable heart failure treated with digitalis, but not diuretics or vasodilators.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Francis GS, Goldsmith SR, Levine TB, et al. Ann Intern Med 1984; 101:370.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyponatremia associated with reduced survival in patients with severe chronic heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 243px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival over time in patients with severe chronic heart failure and a left ventricular ejection fraction less than 30 percent who, at study entry, had either a normal plasma sodium concentration (greater than 137 meq/L, solid line) or hyponatremia (plasma sodium less than or equal to 137 meq/L, dashed line). Survival was significantly reduced in the patients with hyponatremia. The survival rate was very low (approximately 15 percent at 12 months) in those with a baseline plasma sodium concentration less than or equal to 130 meq/L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lee WH, Packer M. Circulation 1986; 73:257.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Plasma NE concentration predicts survival in patients with HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 405px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of norepinephrine (NE). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma NE.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Anand IS, Fisher LD, Chiang YT, et al. Circulation 2003; 107:1278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Plasma BNP concentration predicts survival in patients with HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 423px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an analysis from the Val-HeFT trial, patients with NYHA class II to III heart failure (HF) were stratified according to quartiles of plasma concentration of brain natriuretic peptide (BNP). The mortality rates at two years after randomization were significantly higher in higher quartiles of plasma BNP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Anand IS, Fisher LD, Chiang YT, et al. Circulation 2003; 107:1278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Big endothelin-1 predicts outcome in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis shows that the cumulative event-free survival (free of death or prioritization for urgent transplant) in 218 patients with stable, chronic heart failure is higher in those with a big endothelin (ET)-1 concentration &lt;4.3 fmol/ml compared to those with a concentration &ge;4.3 fmol/ml (p &lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hulsmann M, Stanek B, Frey B. J Am Coll Cardiol 1998; 32:1695.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9061=[""].join("\n");
var outline_f8_54_9061=null;
var title_f8_54_9062="Common melanocytic nevi";
var content_f8_54_9062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Common (banal) acquired melanocytic nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Flat junctional nevus with darker pigmentation in the center than at the periphery. B) Compound nevus with central elevation. C) Soft intradermal nevus that is pink in color. All of these lesions are symmetric with a regular outline and uniform pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9062=[""].join("\n");
var outline_f8_54_9062=null;
var title_f8_54_9063="Angle-closure glaucoma";
var content_f8_54_9063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Angle-closure glaucoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9063/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9063/contributors\">",
"     Jennifer S Weizer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9063/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9063/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9063/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/54/9063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angle-closure glaucoma is likely the most common form of glaucoma worldwide, and the leading cause of glaucoma blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States, however, primary angle-closure glaucoma accounts for approximately 10 percent of all glaucoma cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss types of angle-closure glaucoma, diagnosis and treatment. A discussion of open angle glaucoma is presented separately. A table to assist with the emergent management of severe acute open-angle glaucoma is provided (",
"    <a class=\"graphic graphic_table graphicRef74621 \" href=\"UTD.htm?35/19/36156\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p>",
"    Glaucoma is defined as an optic neuropathy involving a characteristic atrophy of the optic nerve head, often accompanied with typical visual field defects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/2\">",
"     2",
"    </a>",
"    ]. Examination of a glaucomatous optic nerve reveals \"cupping\", which looks like a \"hollowing out\" of the optic nerve head (",
"    <a class=\"graphic graphic_picture graphicRef66101 \" href=\"UTD.htm?32/17/33055\">",
"     picture 1",
"    </a>",
"    ). Glaucoma is typically, though not always, associated with elevated intraocular pressure.",
"   </p>",
"   <p>",
"    Angle-closure glaucoma is a form of glaucoma characterized by narrowing or closure of the anterior chamber angle. The normal anterior chamber angle provides drainage for the aqueous humor, the fluid that fills the eyeball. When this drainage pathway is narrowed or closed, inadequate drainage of the aqueous humor leads to elevated intraocular pressure and damage to the optic nerve (",
"    <a class=\"graphic graphic_figure graphicRef71234 graphicRef59454 \" href=\"UTD.htm?16/22/16743\">",
"     figure 1A-B",
"    </a>",
"    ). Normal intraocular pressure is 8 to 21 mm Hg. In acute episodes of closed-angle glaucoma, pressures are often 30 mm Hg or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Types of angle-closure glaucoma",
"    </span>",
"   </p>",
"   <p>",
"    Angle-closure glaucoma is divided into two main groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary angle closure &mdash; Patients are anatomically predisposed to this type of glaucoma; there is no identifiable secondary cause.",
"     </li>",
"     <li>",
"      Secondary angle closure &mdash; A secondary process is responsible for narrowing or closure of the anterior chamber angle. Examples of secondary causes are a fibrovascular membrane that grows over the angle to pull it closed, as in neovascular glaucoma, or a mass or hemorrhage in the posterior segment of the eyeball that pushes the angle closed [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors that predispose to primary angle-closure glaucoma include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of angle closure",
"     </li>",
"     <li>",
"      Age older than 40 to 50 years",
"     </li>",
"     <li>",
"      Female",
"     </li>",
"     <li>",
"      Hyperopia (farsightedness)",
"     </li>",
"     <li>",
"      Certain medications, particularly over-the-counter decongestants, motion sickness medications, adrenergic agents, antipsychotics, antidepressants, and anticholinergic agents",
"     </li>",
"     <li>",
"      Pseudoexfoliation (a condition in which abnormal flaky deposits on eye surfaces can weaken the zonules that support the lens and cause it to shift forward)",
"     </li>",
"     <li>",
"      Race",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The highest rates of angle closure are reported in Inuit and Asian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/1,5-8\">",
"     1,5-8",
"    </a>",
"    ], and lower rates are reported in populations of African and European origin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/2,6,9,10\">",
"     2,6,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary angle closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aqueous humor is produced by the ciliary body, flows through the pupil, reaches the anterior chamber angle and exits the eye. The balance between fluid production and drainage determines the intraocular pressure.",
"   </p>",
"   <p>",
"    In primary angle closure, the lens is located too far forward anatomically and rests against the iris. This results in pupillary block, a condition in which aqueous humor can no longer flow normally through the pupil. Pressure builds up behind the iris, relative to the anterior chamber, causing the peripheral iris to bow forward and cover all or part of the anterior chamber angle.",
"   </p>",
"   <p>",
"    Prolonged or repeated contact between the iris and the angle can lead to scarring and functional damage to the trabecular meshwork, the tissue in the angle that acts as a sieve through which the aqueous humor drains (",
"    <a class=\"graphic graphic_figure graphicRef71234 graphicRef59454 \" href=\"UTD.htm?16/22/16743\">",
"     figure 1A-B",
"    </a>",
"    ). Once the optic nerve shows damage from the high intraocular pressure, the disease is called primary angle closure glaucoma.",
"   </p>",
"   <p>",
"    If the entire angle is blocked suddenly, as occurs in complete pupillary block, the intraocular pressure rises rapidly, and acute symptoms can occur. These attacks of acute angle closure may resolve spontaneously and recur repeatedly if not treated. Without treatment, vision loss and even blindness can occur quickly during the attack (over hours to days), so acute angle closure is a true ophthalmic emergency.",
"   </p>",
"   <p>",
"    Patients with anatomically narrow angles are at risk for future angle closure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/2\">",
"     2",
"    </a>",
"    ]. The width of their anterior chamber angle is smaller than in the normal eye, and the peripheral iris is closer to the anterior chamber angle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chronic angle closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic angle closure results if only a portion of the angle is blocked at a time and develops scarring. Over time, the angle may become progressively more closed. In this variation of the disease, the intraocular pressure may be normal or only slightly elevated, in which case symptoms will likely not occur. Patients with chronic angle closure glaucoma may have more damage to the optic nerve and peripheral vision when the diagnosis is established, compared to patients with symptomatic acute glaucoma, due to absence of symptoms, and thus delayed presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Secondary angle closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary angle closure glaucoma results when the anterior chamber angle becomes occluded as the result of conditions that push the iris or ciliary body forward (\"pushing\" conditions) or deform the iris so that it is retracted into the angle (\"pulling\" conditions).",
"   </p>",
"   <p>",
"    Pushing conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrosis of the pupil to the anterior surface of the lens",
"     </li>",
"     <li>",
"      Choroidal swelling or hemorrhage (due to types of ophthalmic surgery, retinal laser treatment, posterior scleritis, or drug reactions).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      is the most common of the sulfa-based medications to cause this rare, idiosyncratic reaction.",
"     </li>",
"     <li>",
"      Plateau iris syndrome (a developmental anomaly)",
"     </li>",
"     <li>",
"      A large or anteriorly displaced lens",
"     </li>",
"     <li>",
"      Aqueous misdirection (in which aqueous humor fills the vitreous cavity instead of flowing through the pupil, most commonly as a result of ophthalmic surgery)",
"     </li>",
"     <li>",
"      Choroidal hemorrhage or effusion",
"     </li>",
"     <li>",
"      A space-occupying lesion in the posterior segment of the eyeball (such as a tumor or a gas bubble placed during retinal surgery)",
"     </li>",
"     <li>",
"      Developmental syndromes causing fibrosis in the posterior segment of the eyeball",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulling conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation or blood in the angle itself that fibroses and contracts",
"     </li>",
"     <li>",
"      Neovascularization of the iris with a resulting fibrovascular membrane (most commonly seen in poorly controlled diabetes mellitus or ophthalmic artery insufficiency)",
"     </li>",
"     <li>",
"      Abnormal corneal endothelial cell proliferation",
"     </li>",
"     <li>",
"      Prolonged shallowing of the anterior chamber resulting in iris-angle contact due to trauma or surgery",
"     </li>",
"     <li>",
"      Epithelial cell or fibroblast invasion of the angle [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapidity and degree of the intraocular pressure elevation from angle closure determines whether symptoms occur. If the intraocular pressure rises quickly, as is typical of acute primary angle closure, patients may experience some or all of the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased vision",
"     </li>",
"     <li>",
"      Halos around lights",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Severe eye pain",
"     </li>",
"     <li>",
"      Nausea and vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the rise in intraocular pressure is slower and does not reach very high levels, the patient may be symptom-free. This occurs in chronic angle closure glaucoma. The patient may not notice damage to the peripheral vision, which generally precedes decrease in central vision.",
"   </p>",
"   <p>",
"    Signs that suggest a rapid rise in intraocular pressure include (",
"    <a class=\"graphic graphic_picture graphicRef80395 \" href=\"UTD.htm?22/50/23328\">",
"     picture 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conjunctival redness",
"     </li>",
"     <li>",
"      Corneal edema or cloudiness",
"     </li>",
"     <li>",
"      A shallow anterior chamber",
"     </li>",
"     <li>",
"      A mid-dilated pupil (4 to 6 mm) that reacts poorly to light",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signs and symptoms of acute glaucoma often occur in the evening, when lower light levels cause mydriasis, and folds of the peripheral iris block the narrow angle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    Patients with the above signs or symptoms should undergo emergent ophthalmic examination of both eyes by an ophthalmologist, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Visual acuity",
"     </li>",
"     <li>",
"      Evaluation of the pupils",
"     </li>",
"     <li>",
"      Intraocular pressure",
"     </li>",
"     <li>",
"      Slit lamp examination of the anterior segments",
"     </li>",
"     <li>",
"      Visual field testing (either by confrontation [finger testing] or by formal methods, depending on the acuteness of the clinical situation)",
"     </li>",
"     <li>",
"      Gonioscopy (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Gonioscopy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Undilated fundus examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pupillary dilation should be deferred in untreated cases of suspected angle closure, as this may exacerbate the condition.",
"   </p>",
"   <p>",
"    On eye examination, patients who have experienced prior acute attacks of high intraocular pressure may demonstrate iris irregularity due to ischemia during the attack, glaucomflecken (scattered opacities) in the anterior lens, normal or increased intraocular pressure, and cupping of the optic disc if narrow-angle glaucoma is present.",
"   </p>",
"   <p>",
"    Although angle closure often presents in just one eye, it is important to examine the fellow eye as well. The angle of the fellow eye may be similarly narrow, putting this eye at risk for future angle-closure attacks unless prophylactic treatment is instituted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gonioscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonioscopy is the gold-standard method of diagnosing angle closure. This technique involves using a special lens for the slit lamp, which allows the ophthalmologist to visualize the angle and diagnose angle closure (",
"    <a class=\"graphic graphic_picture graphicRef77383 \" href=\"UTD.htm?28/60/29635\">",
"     picture 3",
"    </a>",
"    ). Indentation gonioscopy refers to putting posterior pressure on the eyeball with the lens used for gonioscopy. The pressure will widen the angle if it is not scarred completely closed; the extent to which scarring has produced angle closure helps to determine the severity and chronicity of the angle closure. Gonioscopy requires expertise and experience to perform reliably.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Slit lamp grading of anterior chamber depth",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this technique, the width of the angle is estimated by shining a light beam from the slit lamp on the peripheral anterior chamber. It is not as reliable as gonioscopy for diagnosing angle closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ultrasound biomicroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized ultrasound of the anterior chamber can show angle closure and help to define the mechanism. The ultrasound biomicroscope instrument is costly and thus not widely available. This technique also requires specialized interpretation of the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Provocative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocative tests most often do not provide additional information beyond the clinical examination, and are not widely used because of their risks. In the dark room provocation test, a patient rests (awake) in a dark room for 30 minutes with his or her head in the prone position to encourage pupillary dilation and forward displacement of the lens. Angle closure is suggested if the intraocular pressure rises significantly or if the angle appears more closed on gonioscopy. Clinical applicability is unknown.",
"   </p>",
"   <p>",
"    In pharmacological tests, the pupil is dilated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or parasympatholytic mydriatic eye drops and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    is instilled in an attempt to provoke an attack of angle closure. This procedure involves risk and a negative result does not absolutely rule out angle closure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/4\">",
"     4",
"    </a>",
"    ]. Both eyes should not be tested simultaneously. We do not recommend this test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Investigational",
"    </span>",
"    &nbsp;&mdash;&nbsp;High definition anterior segment optical coherence tomography is being developed as a modality to image the drainage angle and detect eyes at risk for angle closure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/12\">",
"     12",
"    </a>",
"    ]. This imaging technology has led to findings suggesting that eyes prone to developing angle closure do not merely differ anatomically from normal eyes but may also respond differently to light stimuli. As an example, when dilated to the same degree, the iris of an angle closure eye tends to be thicker than the iris of a normal eye [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    Other causes of a red eye may mimic acute primary angle glaucoma. These include iritis, traumatic hyphema, conjunctivitis, episcleritis, subconjunctival hemorrhage, corneal abrasion, and infectious keratitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary care clinician may be able to distinguish acute primary closure from these conditions by the presence of severe eye pain, headache, nausea and vomiting, a mid-dilated pupil, and possibly decreased vision. Not every patient with acute angle closure will demonstrate all of these signs and symptoms, however.",
"   </p>",
"   <p>",
"    Secondary causes of angle closure are best differentiated from primary angle closure by an ophthalmologist (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Secondary angle closure'",
"    </a>",
"    above). The treatment of these disorders differs from treatment of primary angle closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of angle closure involves prevention or reversal of angle closure, as well as control of intraocular pressure. A table to assist with the emergent management of severe acute open-angle glaucoma is provided (",
"    <a class=\"graphic graphic_table graphicRef74621 \" href=\"UTD.htm?35/19/36156\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute primary angle closure glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no available trials comparing medical options for treatment of acute angle closure, and treatment recommendations are based on clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/14\">",
"     14",
"    </a>",
"    ]. When an ophthalmologist is available for consultation within one hour of patient presentation, patients with signs or symptoms suggesting possible acute angle closure should be referred for emergent assessment and treatment.",
"   </p>",
"   <p>",
"    When there is likely to be an hour or more delay before a patient can be seen by an ophthalmologist, and the suspicion of an acute attack is high, empiric treatment should be initiated. For an acute primary angle closure attack, initial management involves prompt administration of pressure-lowering eye drops. A possible regimen would be one drop each, one minute apart, of [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0.5%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      maleate (Timoptic)",
"     </li>",
"     <li>",
"      1%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/28/36291?source=see_link\">",
"       apraclonidine",
"      </a>",
"      (Iopidine), and",
"     </li>",
"     <li>",
"      2%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      (Isopto Carpine)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic medications (oral or IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , or oral glycerol or isosorbide) to control the intraocular pressure are often given. We suggest giving the patient two 250 mg tablets of acetazolamide in the office. The eye pressure should be checked 30 to 60 minutes after giving pressure-lowering drops and oral acetazolamide. Systemic medications other than oral acetazolamide should be administered under the guidance of an ophthalmologist, since angle closure should be confirmed before they are given.",
"   </p>",
"   <p>",
"    If medical treatment is successful in reducing intraocular pressure, as is most often the case, corneal edema and eye pain will typically lessen or resolve. Once the attack is broken, the treatment of choice is a peripheral iridotomy. If laser peripheral iridotomy fails to remain patent, or the cornea is too cloudy to visualize the iris, surgical peripheral iridectomy may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Laser peripheral iridotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure creates a tiny hole in the peripheral iris through which aqueous humor can flow and reach the angle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/15\">",
"     15",
"    </a>",
"    ]. Once the iridotomy is patent, pupillary block is bypassed. Peripheral iridotomy is usually created with a laser.",
"   </p>",
"   <p>",
"    The intraocular pressure is rechecked 30 to 120 minutes after the iridotomy is performed, and mild steroid drops are given for several days. Repeat gonioscopy is then performed to determine if the angle is wider. The pupil is dilated to ensure that the intraocular pressure does not rise significantly, and to better assess any glaucoma damage to the optic nerve.",
"   </p>",
"   <p>",
"    Possible complications of laser peripheral iridotomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased intraocular pressure",
"     </li>",
"     <li>",
"      Inflammation",
"     </li>",
"     <li>",
"      Laser burns to the cornea, lens, or retina",
"     </li>",
"     <li>",
"      A ghost image in the vision",
"     </li>",
"     <li>",
"      Increased rate of cataract formation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Need for repeat treatment if the hole were to shrink or close spontaneously",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The fellow eye should be examined. If a narrow angle is found, prophylactic laser peripheral iridotomy should be performed to prevent future attacks of angle closure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/16\">",
"     16",
"    </a>",
"    ]. Untreated, approximately 50 percent of fellow eyes in acute angle-closure patients will have an angle-closure attack within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a few cases of angle closure, goniosynechialysis may be performed in the operating room at some point after a peripheral iridotomy is in place. In goniosynechialysis, adhesions that result in scarring of the angle are mechanically lysed in an attempt to restore some drainage function. Results tend to be better if the scarring has been present for less than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cataract surgery (phacoemulsification) with an intraocular lens implant also may resolve the issue of acute or chronic primary angle closure, once diagnosed, by removing the lens that may be crowding the angle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/16,18-20\">",
"     16,18-20",
"    </a>",
"    ]. A randomized trial of 62 Chinese patients with cataracts who had been medically treated for acute primary angle closure found that early phacoemulsification was more effective than laser peripheral iridotomy in preventing recurrence of intraocular pressure rise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/21\">",
"     21",
"    </a>",
"    ]. The role of phacoemulsification as definitive treatment following an episode of angle closure, especially in patients without significant cataracts, remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chronic angle closure glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser peripheral iridotomy is the first step in treatment of patients with chronic angle closure glaucoma, to relieve any pupillary block component. The intraocular pressure may remain elevated, however, if scarring has already damaged the drainage angle. In this case, the remaining glaucoma is treated medically and surgically much as in open-angle glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Secondary angle closure glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary angle closure is managed by treating the cause of the angle closure if possible. Controlling the intraocular pressure medically and surgically afterwards is the next step, much as in open-angle glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PATIENT INSTRUCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are known to have narrow angles but who have not yet undergone laser peripheral iridotomy should avoid medicines that induce pupillary dilation and might provoke an angle-closure attack. Such medicines include over-the-counter decongestants, motion sickness medications, adrenergic agents, antipsychotics, antidepressants, and anticholinergic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9063/abstract/2\">",
"     2",
"    </a>",
"    ]. Once laser peripheral iridotomy has been performed, these medications are no longer contraindicated.",
"   </p>",
"   <p>",
"    People with a family history of primary angle closure should undergo regular screening eye examinations for this condition, particularly as they reach middle age. The examining ophthalmologist should perform gonioscopy to assess for narrow angles, and evidence of prior angle closure; laser peripheral iridectomy should be performed if these are found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes of patients with angle closure depend on how early the disease is detected. Because glaucoma damage to the optic nerve is generally not reversible and can occur within a matter of hours in the case of an acute angle closure attack, it is important that an ophthalmologist see these patients emergently to provide prompt diagnosis and treatment.",
"   </p>",
"   <p>",
"    The fellow eye also must be evaluated as prophylactic treatment with laser peripheral iridotomy can prevent future angle closure. The outcome for patients with secondary angle closure depends on the cause of the angle closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/46/26337?source=see_link\">",
"       \"Patient information: Angle-closure glaucoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glaucoma involves a characteristic atrophy of the optic nerve head (\"cupping\"), often with peripheral vision defects. Angle-closure glaucoma is characterized by narrowing or closure of the anterior chamber angle, leading to elevated intraocular pressure and damage to the optic nerve. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drainage of aqueous humor through the anterior angle is blocked by anatomic narrowing of the angle in primary angle-closure glaucoma. Acute blockage is an ophthalmic emergency, since vision loss and blindness may occur quickly. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Primary angle closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic angle closure may not develop elevated intraocular pressure and symptoms, and diagnosis may be delayed resulting in more vision loss than patients with acute angle closure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic angle closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary angle closure is caused by a variety of processes that either push or pull the anterior chamber angle closed. These may include fibrosis and scarring, drug reactions, neovascularization, or mass. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Secondary angle closure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute angle-closure glaucoma present with vision loss, headache, severe eye pain, light halos, nausea, and vomiting. Exam reveals a red eye, corneal cloudiness or edema, a shallow anterior chamber, and poorly reactive mid dilated pupil. Ophthalmologic examination is needed emergently. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of angle-closure glaucoma is established by gonioscopy. Provocative tests are not recommended. The fellow eye should be examined as well as the affected eye. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with signs and symptoms suggesting an acute attack of angle-closure glaucoma require emergency treatment by an ophthalmologist. A table to assist with the emergent management of severe acute open-angle glaucoma is provided (",
"      <a class=\"graphic graphic_table graphicRef74621 \" href=\"UTD.htm?35/19/36156\">",
"       table 1",
"      </a>",
"      ). We recommend emergency use of topical ophthalmic medications to reduce intraocular pressure (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). These drugs may include a beta-blocker, an alpha agonist, and an agent to produce miosis. We also suggest systemic medication to decrease intraocular pressure, which may include oral or IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      , IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , oral glycerol, or isosorbide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Once the acute attack is controlled, definitive treatment for angle-closure glaucoma is a laser peripheral iridotomy to provide a small drainage hole through the iris. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with narrow anterior chamber angles, who are awaiting surgery, should be advised to avoid decongestants and anticholinergic medications, which may precipitate an attack. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Patient instructions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/1\">",
"      Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol 2001; 85:1277.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Ophthalmology. Primary angle closure, preferred practice pattern. American Academy of Ophthalmology, San Francisco 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/3\">",
"      Pokhrel PK, Loftus SA. Ocular emergencies. Am Fam Physician 2007; 76:829.",
"     </a>",
"    </li>",
"    <li>",
"     Traverso CE, Bagnis A, Bricola G. Angle-closure glaucoma. In: Ophthalmology, 2nd ed, Yanoff (Ed), Mosby, 2004. p.1491.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/5\">",
"      Bourne RR, S&oslash;rensen KE, Klauber A, et al. Glaucoma in East Greenlandic Inuit--a population survey in Ittoqqortoormiit (Scoresbysund). Acta Ophthalmol Scand 2001; 79:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/6\">",
"      Congdon N, Wang F, Tielsch JM. Issues in the epidemiology and population-based screening of primary angle-closure glaucoma. Surv Ophthalmol 1992; 36:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/7\">",
"      Congdon NG, Friedman DS. Angle-closure glaucoma: impact, etiology, diagnosis, and treatment. Curr Opin Ophthalmol 2003; 14:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/8\">",
"      Wang JC, Chew PT. What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model. Clin Experiment Ophthalmol 2004; 32:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/9\">",
"      Buhrmann RR, Quigley HA, Barron Y, et al. Prevalence of glaucoma in a rural East African population. Invest Ophthalmol Vis Sci 2000; 41:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/10\">",
"      Bonomi L, Marchini G, Marraffa M, et al. Epidemiology of angle-closure glaucoma: prevalence, clinical types, and association with peripheral anterior chamber depth in the Egna-Neumarket Glaucoma Study. Ophthalmology 2000; 107:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/11\">",
"      Leibowitz HM. The red eye. N Engl J Med 2000; 343:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/12\">",
"      Wong HT, Lim MC, Sakata LM, et al. High-definition optical coherence tomography imaging of the iridocorneal angle of the eye. Arch Ophthalmol 2009; 127:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/13\">",
"      Quigley HA, Silver DM, Friedman DS, et al. Iris cross-sectional area decreases with pupil dilation and its dynamic behavior is a risk factor in angle closure. J Glaucoma 2009; 18:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/14\">",
"      Shields SR. Managing eye disease in primary care. Part 3. When to refer for ophthalmologic care. Postgrad Med 2000; 108:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/15\">",
"      Quigley HA. Glaucoma. Lancet 2011; 377:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/16\">",
"      Saw SM, Gazzard G, Friedman DS. Interventions for angle-closure glaucoma: an evidence-based update. Ophthalmology 2003; 110:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/17\">",
"      Edwards RS. Behaviour of the fellow eye in acute angle-closure glaucoma. Br J Ophthalmol 1982; 66:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/18\">",
"      Teekhasaenee C, Ritch R. Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-closure glaucoma after acute angle-closure glaucoma. Ophthalmology 1999; 106:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/19\">",
"      Lai JS, Tham CC, Chan JC. The clinical outcomes of cataract extraction by phacoemulsification in eyes with primary angle-closure glaucoma (PACG) and co-existing cataract: a prospective case series. J Glaucoma 2006; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/20\">",
"      Friedman DS, Vedula SS. Lens extraction for chronic angle-closure glaucoma. Cochrane Database Syst Rev 2006; :CD005555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9063/abstract/21\">",
"      Lam DS, Leung DY, Tham CC, et al. Randomized trial of early phacoemulsification versus peripheral iridotomy to prevent intraocular pressure rise after acute primary angle closure. Ophthalmology 2008; 115:1134.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6903 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9063=[""].join("\n");
var outline_f8_54_9063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Types of angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary angle closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chronic angle closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Secondary angle closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gonioscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Slit lamp grading of anterior chamber depth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ultrasound biomicroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Provocative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Investigational",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute primary angle closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Laser peripheral iridotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chronic angle closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Secondary angle closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PATIENT INSTRUCTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6903|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/60/11201\" title=\"figure 1A\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/50/40738\" title=\"figure 1B\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6903|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/17/33055\" title=\"picture 1\">",
"      Optic disk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/50/23328\" title=\"picture 2\">",
"      Angle closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/60/29635\" title=\"picture 3\">",
"      Gonioscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/19/36156\" title=\"table 1\">",
"      Emerg rx acute angle closure glaucoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/46/26337?source=related_link\">",
"      Patient information: Angle-closure glaucoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_54_9064="Diagnosis and evaluation of the sick sinus syndrome";
var content_f8_54_9064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and evaluation of the sick sinus syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9064/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9064/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9064/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9064/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/54/9064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sick sinus syndrome (SSS) is characterized by dysfunction of the sinoatrial (SA) node that is often secondary to senescence of the SA node and surrounding atrial myocardium. The term \"sick sinus syndrome\" was first used in 1967 to describe the sluggish return of SA nodal activity in some patients following electrical cardioversion, and was later applied to a clinical syndrome characterized by chronic SA node dysfunction, a sluggish or absent SA nodal pacemaker after electrical cardioversion frequently depressed escape pacemakers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atrioventricular (AV) nodal conduction disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These abnormalities can result in profound sinus bradycardia, sinus pauses, sinus arrest, SA nodal exit block, and inappropriate responses to physiological demands during exercise or stress. SSS can also be accompanied by AV nodal conduction disturbances and by paroxysmal supraventricular tachycardia as part of the tachycardia-bradycardia syndrome.",
"   </p>",
"   <p>",
"    The initial clues to the diagnosis of SSS are often clinical, as patients may present with symptoms of fatigue, lightheadedness, presyncope, syncope, dyspnea on exertion, angina,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palpitations. A routine electrocardiogram (ECG)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ambulatory ECG monitoring may provide further information in such patients. However, the symptoms are nonspecific and the ECG changes may not be diagnostic, thereby necessitating either noninvasive or electrophysiologic studies to confirm the diagnosis. Prior to any testing, a thorough evaluation should be performed for remediable causes, which include the use of medications (eg, beta blockers, calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , antiarrhythmics), myocardial ischemia, systemic illness (eg, hypothyroidism), and autonomic imbalance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=see_link\">",
"     \"Sinoatrial nodal pause, arrest, and exit block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis and evaluation of SSS, which includes both physiologic and pharmacologic testing, will be reviewed here. The clinical manifestations, causes, and natural history of SSS; the electrophysiologic evaluation of SSS; the treatment of SSS; and the appropriate timing of referral to a specialist are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link&amp;anchor=H9#H9\">",
"     \"Arrhythmia management for the primary care clinician\", section on 'Referral to a specialist'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different modalities have been used in the evaluation of suspected SSS (",
"    <a class=\"graphic graphic_table graphicRef57460 \" href=\"UTD.htm?13/37/13916\">",
"     table 1",
"    </a>",
"    ). Following is a review of these techniques and a simplified diagnostic approach for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3789410\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SSS in persons with suggestive symptoms is often made from the surface electrocardiogram (ECG). The typical clinical manifestations and ECG findings are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=see_link\">",
"     \"Sinoatrial nodal pause, arrest, and exit block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117942113\">",
"    <span class=\"h2\">",
"     Ambulatory ECG monitoring and event recording",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ambulatory ECG monitoring in diagnosing SSS has the potential advantages of prolonged ECG monitors for days to weeks and allows for the correlation of symptoms with cardiac arrhythmias. In some instances where the symptoms are very infrequent, the use of implantable event monitors have been used that allow for monitoring periods of greater than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients suspected of having SSS, ambulatory ECG monitoring may provide important clues in 50 to 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, correlation of symptoms with the electrocardiographic event is infrequent, and the specificity of the 24-hour monitor is low [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of cardiac event monitors has been shown to be more effective than 24-hour continuous monitors in establishing a diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. We frequently use an event recorder to try to capture the ECG during a symptomatic episode, but this approach needs to be studied systematically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17556855\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that a subnormal increase in heart rate after exercise (ie, chronotropic incompetence) may be useful in diagnosing SSS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. While there are various definitions on what is considered subnormal, most clinicians diagnose chronotropic incompetence as either a monotonic heart rate over a 24-hour period or the inability of achieving at least 80 percent of the maximum predicted heart rate with exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/13\">",
"     13",
"    </a>",
"    ]. The sensitivity and specificity of this latter approach, however, are uncertain, and the results obtained may not be reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs have been used in the assessment of SSS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      &mdash; Atropine (1 or 2 mg) and isoproterenol (2 to 3",
"      <span class=\"nowrap\">",
"       &micro;g/min)",
"      </span>",
"      may be useful, since both agents normally increase the sinus rate [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. A suggested abnormal response is an increase in the sinus rate of less than 25 percent, or to a rate below 90",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      There are, however, a number of potential problems. There has been no standardization of the pharmacologic testing, no dose ranging has been reported, the specificity and sensitivity of the tests are uncertain, and SSS may exist even if the response is normal. In addition, isoproterenol is not without risk in patients with ischemic and other types of heart disease.",
"     </li>",
"     <li>",
"      Adenosine &mdash; Adenosine should be considered as an alternative to invasive testing in patients with suspected SSS. Adenosine directly inhibits sinus node activity, with its effects mediated by increased potassium conductance and a resulting hyperpolarization of the resting membrane potential. One study of 10 patients with an SSS and 67 control subjects found that a corrected sinus node recovery time &gt;550 msec had a sensitivity and specificity of 80 and 97 percent, respectively, for detecting SSS; in comparison, the sensitivity and specificity for invasively obtained corrected sinus node recovery time was 70 and 95 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/17\">",
"       17",
"      </a>",
"      ]. When the two tests were combined, the sensitivity was 100 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22328?source=see_link&amp;anchor=H4#H4\">",
"       \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\", section on 'Sinus node dysfunction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intrinsic heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrinsic heart rate (IHR) is the heart rate in the presence of complete pharmacological denervation of the sinus node. This is achieved with the simultaneous use of beta blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . Typically, atropine (0.04",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    are used, and the rate achieved after 30 minutes of drug exposure is defined as the IHR [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Often the IHR is faster than the resting heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The IHR is a function of age and can be determined from the equation:",
"   </p>",
"   <p>",
"    &nbsp;IHR, in",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    = 117.2 - [0.53 x age]",
"   </p>",
"   <p>",
"    It has been suggested that the IHR may separate patients with intrinsic SSS (reflecting primary SA node dysfunction) from those who have bradycardia and extrinsic SSS due to increased parasympathetic tone or drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/22\">",
"     22",
"    </a>",
"    ]. This hypothesis is supported by the correlation between the IHR and the rate of the denervated sinus node after cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/23\">",
"     23",
"    </a>",
"    ]. Intrinsic SSS is presumed to be present if the sinus rate does not exceed the predicted IHR after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ; a normal IHR suggests extrinsic SSS. Whether the use of atropine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in combination provides more information than the use of atropine alone in this setting is uncertain.",
"   </p>",
"   <p>",
"    In patients with deficient chronotropic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    administration, it has been suggested that the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    tests may identify individuals with inadequate chronotropic reserves [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/24\">",
"     24",
"    </a>",
"    ]. The authors suggest that this group may possibly require preventive pacemaker implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557141\">",
"    <span class=\"h2\">",
"     Electrophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive electrophysiologic studies (EPS) are infrequently used for the evaluation of SSS (eg, symptomatic patient who has no electrocardiographic findings suggestive of SSS but no other evident cause for the symptoms) because of their limited sensitivity in eliciting bradyarrhythmic abnormalities. The salient points of invasive EPS for the diagnosis of SSS are discussed here, with a comprehensive review of invasive EPS presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22328?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17558344\">",
"    <span class=\"h3\">",
"     Indications for EPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for EPS in a patient with suspected SSS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The symptomatic patient who has no electrocardiographic findings suggestive of SSS and no other evident cause for the symptoms.",
"     </li>",
"     <li>",
"      The symptomatic patient in whom electrocardiographic events compatible with SSS fail to correlate with symptoms.",
"     </li>",
"     <li>",
"      The symptomatic patient with SSS who has normal sinus rhythm while asymptomatic. If SA nodal function is normal, autonomic testing should be performed. Some patients, particularly those with excessive vagal tone, may be manageable with medical therapy.",
"     </li>",
"     <li>",
"      The patient who develops dysfunction of the SA node on usual doses of digitalis, beta blockers, calcium channel blockers, and antiarrhythmic drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient with suspected SSS associated with paroxysmal atrial fibrillation or flutter who does not demonstrate SA nodal dysfunction but who may require the use of a drug (such as an antiarrhythmic agent) that may unmask SA nodal dysfunction.",
"     </li>",
"     <li>",
"      The patient with syncope or near syncope who has bundle branch or multifascicular block may require electrophysiologic evaluation of the SA node, the AV node, and the infranodal His-bundle-Purkinje system intervals and conduction. Electrophysiologic testing that shows SA nodal dysfunction allows the selection of appropriate therapy in up to 50 percent of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient with syncope or near syncope who has ventricular arrhythmias may require provocative electrophysiologic ventricular studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The salient aspects of electrophysiology studies that aid in eliciting a bradyarrhythmic abnormality include assessment of the sinoatrial node recovery time, sinoatrial conduction time, and the sinus node and atrial tissue refractory periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557864\">",
"    <span class=\"h3\">",
"     Sinoatrial node recovery time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SNRT is perhaps the most useful test of overall sinus nodal automaticity. The concept is simple. The atria are driven rapidly; a normal SA node will have a recovery time within certain limits, while recovery will be delayed in a depressed or sick sinus node.",
"   </p>",
"   <p>",
"    Overdrive stimulation is performed at a rate higher than that of the SA node for about one minute (the range in most published reports is 30 to 180 sec). Pacing is then stopped, and the time from the last paced atrial beat to the first spontaneous electrical beat with a sinus morphology is measured. Pacing is increased 10 to 20",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    up to 200",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    if tolerated. The SNRT may be corrected by subtracting the sinus cycle length from the SNRT (SNRTc) or by expressing it as a function of the cycle length, that is,",
"    <span class=\"nowrap\">",
"     SNRT/sinus",
"    </span>",
"    cycle length. A number of criteria have been suggested, but the normal values are quite broad. In general, the SNRT should be less than 1600 or 1700 msec, and the SNRTc less than 450 msec. The SNRT or SNRTc is abnormal in more than 50 percent of patients with suspected SSS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/25-30\">",
"     25-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overdrive suppression, used in conjunction with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , may increase the sensitivity of the test and its potential to diagnose a SSS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/31\">",
"     31",
"    </a>",
"    ]. The noninvasive determination of the sinus cycle length, corrected to the basic cycle length, after a bolus of adenosine is also an indicator of SSS. In one study of 77 patients, it had a sensitivity and specificity of 80 and 97 percent, respectively, which was comparable to those of SNRTc obtained invasively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determination of the intrinsic heart rate (IHR) can help to distinguish between extrinsic and intrinsic defects in SA nodal function. The IHR is normal with extrinsic and abnormal with intrinsic SSS. Some patients with extrinsic SSS have an abnormal SNRT that normalizes after autonomic blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Intrinsic heart rate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The SNRT, however, is determined by a number of factors other than the intrinsic pacemaker function of the SA node, possibly leading to erroneous interpretation. These include: (1) shifts in the sinus pacemaker; (2) the number of stimuli that enter the SA node which, in turn, may alter the intracellular and extracellular ionic activities and perhaps other determinants of automaticity; (3) the hemodynamic effects of atrial pacing, which may induce baroreceptor responses and cause the release of catecholamines; (4) the autonomic nervous system and the release locally of acetylcholine and catecholamines; and (5) the electrophysiologic properties that affect the transmission of impulses into and out of the SA node, possibly resulting in entrance block into the SA node at high pacing rates and other abnormalities. Unfortunately, it is difficult to assess the importance of these factors, and clinical decisions are usually based on the SNRT.",
"   </p>",
"   <p>",
"    Endurance athletes have a higher prevalence of sinus bradycardia and AV nodal conduction abnormalities as compared with untrained individuals. Although these differences are often attributed to autonomic influences, data suggest that these are due, at least in part, to intrinsic physiologic change in the sinus and AV nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link&amp;anchor=H4#H4\">",
"     \"Arrhythmia in athletes\", section on 'Sinus and AV node dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557871\">",
"    <span class=\"h3\">",
"     Sinoatrial conduction time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SACT is defined as the time required for the sinus impulse to activate the atrium. The most commonly used methods are indirect and use an extrastimulus technique [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/33\">",
"     33",
"    </a>",
"    ] or continuous pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extrastimulus technique is based on the following premise. An induced premature atrial beat near the SA node will penetrate the SA node and reset the SA nodal pacemaker. The SA nodal pacemaker will cause local activation followed by a finite amount of time until the beat reaches the atrium and causes atrial depolarization. The SACT consists of the time required to travel from the atrium to the SA node and then the SA node to the atrium. This will be reflected by the time between the premature beat and the beat that results from the reset SA node (A2-A3 interval) minus the preceding SA nodal cycle length (A1-A1 interval) to correct for rate:",
"   </p>",
"   <p>",
"    &nbsp;SACT = (A2-A3 interval) - (A1-A1 interval)",
"   </p>",
"   <p>",
"    Interpretation of the SACT may be complicated by zones in which the premature beat interferes or collides with an emerging sinus beat, resets the SA node, interpolates, and often causes SA nodal echoes. The SACT is the sum of both retrograde and antegrade values and, because of the uncertainty as to whether each is identical, the sum is often reported, although unidirectional conduction times (that is, the SACT divided by 2) are also commonly used. The summed SACT is generally equal to or less than 250 to 300 msec.",
"   </p>",
"   <p>",
"    Constant atrial pacing can also be used to estimate the SACT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/34\">",
"     34",
"    </a>",
"    ]. With this procedure, trains of up to 20 beats at a rate slightly in excess of the intrinsic sinus rate are used, and the post-pacing return cycle is measured. The assumptions, limitations, and values of this approach are similar to those with the extrastimulus technique.",
"   </p>",
"   <p>",
"    The SA nodal electrogram also can be recorded directly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], and the interval from the onset of the upstroke of the electrogram to the initial deflection of a high right atrial recording is taken as the SACT. The unidirectional SACT is usually less than 120 msec.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557878\">",
"    <span class=\"h3\">",
"     Sinus node and atrial refractory period",
"    </span>",
"    &nbsp;&mdash;&nbsp;SA nodal refractoriness has been determined using both the extrastimulus and pacing train techniques. Normal subjects have an SNERP of 250 to 350 msec as compared to a value of 500 to 550 msec in patients with the SSS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/8\">",
"     8",
"    </a>",
"    ]. In SSS, atrial refractoriness is little changed, but there may be local disturbances of conduction and a lower vulnerability index, which may explain, in part, the tendency of individuals with sinus node dysfunction to develop atrial fibrillation as part of the natural history [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/38\">",
"     38",
"    </a>",
"    ]. These investigators postulate that the relative normality of atrial refractoriness in contrast to atrial conduction disorders may explain the efficacy of atrial pacing in reducing the recurrence of atrial fibrillation in such individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557885\">",
"    <span class=\"h3\">",
"     Correlation of SNRT and SACT with ECG abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following correlations have been made between sinus dysfunction and electrophysiologic testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with sinus bradycardia that led to symptoms have been found to have a longer SNRT and SACT than those who are asymptomatic.",
"     </li>",
"     <li>",
"      Patients with SA block have a longer SACT, and patients with the tachycardia-bradycardia syndrome have a longer SNRT [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal SA nodal function (prolonged SNRTc",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      SACT) has been found in 82 percent of patients with symptomatic SSS, 50 percent with paroxysmal atrial fibrillation or flutter without sinus bradycardia, 47 percent with sinus bradycardia alone, and only 12 percent with no apparent evidence of SA nodal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17556936\">",
"    <span class=\"h2\">",
"     Carotid sinus massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus massage is typically employed in the context of elucidating a cause for syncope. Its use in the assessment of SSS is not widespread and stems from previous reports describing an association between carotid sinus hypersensitivity and SSS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/41\">",
"     41",
"    </a>",
"    ]. With carotid sinus massage, a pause longer than 3 seconds",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a symptomatic drop in blood pressure are indicative of carotid sinus hypersensitivity. This study has limited specificity in establishing a diagnosis of carotid sinus hypersensitivity as the reason for syncope. Occasionally, otherwise asymptomatic elderly individuals may exhibit sinus pauses greater than 3 seconds in duration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/13\">",
"     13",
"    </a>",
"    ]. Hence, interpretation of the results of carotid sinus massage must be made in the proper clinical context.",
"   </p>",
"   <p>",
"    The technique for performing this test and contraindications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link&amp;anchor=H4#H4\">",
"     \"Vagal maneuvers\", section on 'Carotid sinus massage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Signal-averaged P wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the finding of fractionated endocardial electrograms during invasive electrophysiology studies in patients with SSS, a signal averaged electrocardiogram with analysis of the P wave was examined in a preliminary study of 41 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Long, low amplitude signals early during the signal averaged P wave were found to be characteristic of SSS. In addition, a root mean square voltage for the initial 30 msec and a duration of initial low amplitude signals &lt;4 &micro;V of more than 22 msec had a sensitivity, specificity, positive predictive accuracy, and negative predictive accuracy for the identification of SSS of 76, 91,74, and 93 percent, respectively.",
"   </p>",
"   <p>",
"    A second prospective study of 149 patients with paroxysmal atrial fibrillation found that the incidence of SSS was higher in those with low amplitude atrial early potentials on a signal-averaged P wave (47 versus 5 percent without early potentials) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9064/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity of early potentials for the detection of SSS in patients with paroxysmal atrial fibrillation was 78 and 84 percent, respectively.",
"   </p>",
"   <p>",
"    Despite the preliminary data suggesting a possible role in the diagnosis of SSS, signal-averaged P wave analysis during SAECG is not widely used in the assessment of SSS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ALGORITHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to the diagnosis of SSS remains to be established. Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehensive history and physical examination. Careful review of systemic conditions and medication use should be performed to exclude remediable causes for apparent SSS. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Resting 12-lead ECG and, if non-diagnostic, ambulatory ECG monitoring (24- to 48-hour continuous monitor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transtelephonic event monitors for up to four weeks) should be performed to identify symptomatic episodes of bradycardia and average heart rates over extended periods of surveillance. A diagnosis of SSS can often be made with a good history and ECG findings in the proper clinical context. Treatment typically involves the use of a pacemaker if a symptom-rhythm correlation is found. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"       \"Treatment of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In younger individuals or those with an uncommon presentation, additional testing can be performed including exercise stress testing (for chronotropic incompetence), assessment of the intrinsic heart rate with the use of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"        atropine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"        isoproterenol",
"       </a>",
"      </span>",
"      and beta blockers, and electrophysiologic study. In the absence of definitive data, signal-averaged P wave analysis and carotid sinus massage may ultimately be performed, but the final diagnosis is usually made subjectively using a detailed patient history. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"       \"Patient information: Sick sinus syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557034\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sick sinus syndrome (SSS) is characterized by dysfunction of the sinoatrial (SA) node that is often secondary to senescence of the SA node and surrounding atrial myocardium. The initial clues to the diagnosis of SSS are often clinical, and a routine electrocardiogram (ECG)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ambulatory ECG monitoring may provide further information. However, the symptoms are nonspecific and the ECG changes may not be diagnostic, thereby necessitating either noninvasive or electrophysiologic studies to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of ambulatory ECG monitoring in diagnosing SSS has the potential advantages of prolonged ECG monitors for days to weeks and allows for the correlation of symptoms with cardiac arrhythmias. In patients suspected of having SSS, ambulatory ECG monitoring may provide important clues in 50 to 70 percent of cases. (See",
"      <a class=\"local\" href=\"#H1117942113\">",
"       'Ambulatory ECG monitoring and event recording'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While there are various definitions on what is considered a subnormal heart rate response to exercise, most clinicians diagnose chronotropic incompetence as either a near constant (monotonic) heart rate over a 24-hour period or the inability of achieving at least 80 percent of the maximum predicted heart rate with exercise testing. The sensitivity and specificity of this latter approach, however, are uncertain. (See",
"      <a class=\"local\" href=\"#H17556855\">",
"       'Exercise testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The intrinsic heart rate (IHR) is the heart rate in the presence of complete pharmacological denervation of the sinus node. This is achieved with the simultaneous use of beta blockers and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      . The IHR may separate patients with intrinsic SSS (reflecting primary SA node dysfunction) from those who have bradycardia and extrinsic SSS due to increased parasympathetic tone or drugs. Intrinsic SSS is presumed to be present if the sinus rate does not exceed the predicted IHR after atropine. A normal IHR suggests extrinsic SSS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intrinsic heart rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive electrophysiologic studies (EPS) are infrequently used for the evaluation of SSS (eg, symptomatic patient who has no electrocardiographic findings suggestive of SSS but no other evident cause for the symptoms). The salient points of invasive EPS and finding a diagnosis of SSS, are summarized in the text. (See",
"      <a class=\"local\" href=\"#H17557141\">",
"       'Electrophysiologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carotid sinus massage and evaluation of the signal-averaged P wave from a signal-averaged electrocardiogram are sometimes helpful in the diagnosis of SSS when doubt regarding the diagnosis persists after other testing. (See",
"      <a class=\"local\" href=\"#H17556936\">",
"       'Carotid sinus massage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Signal-averaged P wave'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to the diagnosis of SSS is summarized as follows (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnostic algorithm'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Perform a comprehensive history and physical examination.",
"     </li>",
"     <li>",
"      Carefully review for systemic conditions and medication use as potential remediable causes for apparent SSS.",
"     </li>",
"     <li>",
"      Obtain a resting 12-lead ECG and, if non-diagnostic, proceed with ambulatory ECG monitoring for up to four weeks.",
"     </li>",
"     <li>",
"      Consider additional testing (ie, exercise stress testing, assessment of the intrinsic heart rate with the use of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"        atropine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"        isoproterenol",
"       </a>",
"      </span>",
"      and beta blockers, electrophysiologic study, carotid sinus massage, signal-averaged P wave analysis) if the diagnosis remains uncertain.",
"     </li>",
"     <li>",
"      Referral to a heart rhythm specialist as appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/1\">",
"      Ferrer MI. The sick sinus syndrome in atrial disease. JAMA 1968; 206:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/2\">",
"      Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     Ferrer MI. The Sick Sinus Syndrome, Futura Press, New York 1974.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/4\">",
"      Vavetsi S, Nikolaou N, Tsarouhas K, et al. Consecutive administration of atropine and isoproterenol for the evaluation of asymptomatic sinus bradycardia. Europace 2008; 10:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/5\">",
"      Lipski J, Cohen L, Espinoza J, et al. Value of Holter monitoring in assessing cardiac arrhythmias in symptomatic patients. Am J Cardiol 1976; 37:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/6\">",
"      Reiffel JA, Bigger JT Jr, Cramer M, Reid DS. Ability of Holter electrocardiographic recording and atrial stimulation to detect sinus nodal dysfunction in symptomatic and asymptomatic patients with sinus bradycardia. Am J Cardiol 1977; 40:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/7\">",
"      Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. Am J Cardiol 1984; 53:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/8\">",
"      Kerr CR, Strauss HC. The measurement of sinus node refractoriness in man. Circulation 1983; 68:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/9\">",
"      Kinlay S, Leitch JW, Neil A, et al. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial. Ann Intern Med 1996; 124:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/10\">",
"      Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999; 130:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/11\">",
"      Eraut D, Shaw DB. Sinus bradycardia. Br Heart J 1971; 33:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/12\">",
"      Kay GN. Quantitation of chronotropic response: comparison of methods for rate-modulating permanent pacemakers. J Am Coll Cardiol 1992; 20:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/13\">",
"      Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008; 5:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson, ME. Sinus Node Function. In: Clinical Cardiac Electrophysiology: Techniques and Interpretations, 4th, Lippincott, Williams, &amp; Wilkins, Philadelphia 2008. p.69-92.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/15\">",
"      Dhingra RC, Amat-Y-Leon F, Wyndham C, et al. Electrophysiologic effects of atropine on sinus node and atrium in patients with sinus nodal dysfunction. Am J Cardiol 1976; 38:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/16\">",
"      Talano JV, Euler D, Randall WC, et al. Sinus node dysfunction. An overview with emphasis on autonomic and pharmacologic consideration. Am J Med 1978; 64:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/17\">",
"      Burnett D, Abi-Samra F, Vacek JL. Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome. Am Heart J 1999; 137:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/18\">",
"      Jose AD. Effect of combined sympathetic and parasympathetic blockade on heart rate and cardiac function in man. Am J Cardiol 1966; 18:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/19\">",
"      Jose AD, Taylor RR. Autonomic blockade by propranolol and atropine to study intrinsic myocardial function in man. J Clin Invest 1969; 48:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/20\">",
"      Jose AD, Collison D. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res 1970; 4:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/21\">",
"      Opthof T. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res 2000; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/22\">",
"      Jordan JL, Yamaguchi I, Mandel WJ. Studies on the mechanism of sinus node dysfunction in the sick sinus syndrome. Circulation 1978; 57:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/23\">",
"      Mason JW. Overdrive suppression in the transplanted heart: effect of the autonomic nervous system on human sinus node recovery. Circulation 1980; 62:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/24\">",
"      Pierre B, Fauchier L, Breard G, et al. Implantable loop recorder for recurrent syncope: influence of cardiac conduction abnormalities showing up on resting electrocardiogram and of underlying cardiac disease on follow-up developments. Europace 2008; 10:477.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson, ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 2d ed, Lea &amp; Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     Benditt DG, Milstein S, Goldstein M, et al. Sinus node dysfunction: Pathophysiology, clinical features, evaluation and treatment. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes DP, Jalife J (Eds), Saunders, Electrophysiology: From Cell to Bedside, Zipes, DP, Jalife, J (Eds), Saunders, Philadelphia 1990. p.708.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/27\">",
"      Mandel WJ, Hayakawa H, Allen HN, et al. Assessment of sinus node function in patients with the sick sinus syndrome. Circulation 1972; 46:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/28\">",
"      Kang PS, Gomes JA, El-Sherif N. Differential effects of functional autonomic blockade on the variables of sinus nodal automaticity in sick sinus syndrome. Am J Cardiol 1982; 49:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/29\">",
"      Narula OS, Samet P, Javier RP. Significance of the sinus-node recovery time. Circulation 1972; 45:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/30\">",
"      Gupta PK, Lichstein E, Chadda KD, Badui E. Appraisal of sinus nodal recovery time in patients with sick sinus syndrome. Am J Cardiol 1974; 34:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/31\">",
"      Ishikawa T, Sumita S, Kimura K, et al. Sinus node recovery time assessment by the overdrive suppression test employing an intravenous injection of disopyramide phosphate. Europace 2000; 2:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/32\">",
"      Stein R, Medeiros CM, Rosito GA, et al. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol 2002; 39:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/33\">",
"      Strauss HC, Saroff AL, Bigger JT Jr, Giardina EG. Premature atrial stimulation as a key to the understanding of sinoatrial conduction in man. Presentation of data and critical review of the literature. Circulation 1973; 47:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/34\">",
"      Narula OS, Shantha N, Vasquez M, et al. A new method for measurement of sinoatrial conduction time. Circulation 1978; 58:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/35\">",
"      Hariman RJ, Krongrad E, Boxer RA, et al. Method for recording electrical activity of the sinoatrial node and automatic atrial foci during cardiac catheterization in human subjects. Am J Cardiol 1980; 45:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/36\">",
"      Reiffel JA, Gang E, Gliklich J, et al. The human sinus node electrogram: a transvenous catheter technique and a comparison of directly measured and indirectly estimated sinoatrial conduction time in adults. Circulation 1980; 62:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/37\">",
"      Gomes JA, Hariman RI, Chowdry IA. New application of direct sinus node recordings in man: assessment of sinus node recovery time. Circulation 1984; 70:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/38\">",
"      De Sisti A, Leclercq JF, Fiorello P, et al. Electrophysiologic characteristics of the atrium in sinus node dysfunction: atrial refractoriness and conduction. J Cardiovasc Electrophysiol 2000; 11:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/39\">",
"      Breithardt G, Seipel L, Loogen F. Sinus node recovery time and calculated sinoatrial conduction time in normal subjects and patients with sinus node dysfunction. Circulation 1977; 56:43.",
"     </a>",
"    </li>",
"    <li>",
"     Gomes JA. The sick sinus syndrome and evaluation of the patient with sinus node disorders. In: Cardiology: Physiology, Pharmacology, Diagnosis, Parmley WW, Chatterjee K (Eds), Lippincott, New York 1988. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/41\">",
"      Thormann J, Schwarz F, Ensslen R, Sesto M. Vagal tone, significance of electrophysiologic findings and clinical course in symptomatic sinus node dysfunction. Am Heart J 1978; 95:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/42\">",
"      Centurion OA, Fukatani M, Konoe A, et al. Different distribution of abnormal endocardial electrograms within the right atrium in patients with sick sinus syndrome. Br Heart J 1992; 68:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/43\">",
"      Yamada T, Fukunami M, Kumagai K, et al. Detection of patients with sick sinus syndrome by use of low amplitude potentials early in filtered P wave. J Am Coll Cardiol 1996; 28:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9064/abstract/44\">",
"      Yamada T, Fukunami M, Shimonagata T, et al. Identification of sinus node dysfunction by use of P-wave signal-averaged electrocardiograms in paroxysmal atrial fibrillation: a prospective study. Am Heart J 2001; 142:286.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 896 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9064=[""].join("\n");
var outline_f8_54_9064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17557034\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3789410\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117942113\">",
"      Ambulatory ECG monitoring and event recording",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17556855\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intrinsic heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17557141\">",
"      Electrophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17558344\">",
"      - Indications for EPS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17557864\">",
"      - Sinoatrial node recovery time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17557871\">",
"      - Sinoatrial conduction time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17557878\">",
"      - Sinus node and atrial refractory period",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17557885\">",
"      - Correlation of SNRT and SACT with ECG abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17556936\">",
"      Carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Signal-averaged P wave",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC ALGORITHM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17557034\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/896|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/37/13916\" title=\"table 1\">",
"      Noninvasive evaluation of sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=related_link\">",
"      Arrhythmia management for the primary care clinician",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22328?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=related_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=related_link\">",
"      Sinoatrial nodal pause, arrest, and exit block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_54_9065="Supportive care and oxygenation in acute respiratory distress syndrome";
var content_f8_54_9065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supportive care and oxygenation in acute respiratory distress syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9065/contributors\">",
"     Mark D Siegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9065/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9065/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/54/9065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute respiratory distress syndrome (ARDS) previously had a mortality rate greater than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/1\">",
"     1",
"    </a>",
"    ]. Mortality has since declined [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/2-6\">",
"     2-6",
"    </a>",
"    ], but the precise mortality rate is uncertain because estimates tend to be higher in observational studies than randomized trials (",
"    <a class=\"graphic graphic_figure graphicRef83656 \" href=\"UTD.htm?3/11/3263\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. No single change in the management of ARDS can explain the decrease in mortality, which is likely multifactorial (improved approaches to mechanical ventilation and supportive care) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Berlin Definition of ARDS (published in 2012) has replaced the American-European Consensus Conference&rsquo;s definition of ARDS (published in 1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, it should be recognized that most evidence is based upon prior definitions. The current diagnostic criteria for ARDS are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive care and the treatment of severe hypoxemia in patients with ARDS are discussed here. Epidemiology, diagnosis, etiologies, pathophysiology, clinical manifestations, prognosis, mechanical ventilation, and novel therapies are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"     \"Novel therapies for the acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with ARDS die from respiratory failure alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/3,12-14\">",
"     3,12-14",
"    </a>",
"    ]. More commonly, such patients succumb to their primary illness or to secondary complications such as sepsis or multiorgan system failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ARDS require meticulous supportive care, including intelligent use of sedatives and neuromuscular blockade, hemodynamic management, nutritional support, control of blood glucose levels, expeditious evaluation and treatment of nosocomial pneumonia, and prophylaxis against deep venous thrombosis (DVT) and gastrointestinal (GI) bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of sedative-analgesic medications in critically ill patients, including patients with ARDS, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sedation and analgesia are useful in patients with ARDS because they improve tolerance of mechanical ventilation and decrease oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This was illustrated by a study of seven critically ill patients, which found that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    reduced resting and total energy expenditure by 6 and 8.6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since many patients with ARDS require sedation for several days or longer, long-acting relatively inexpensive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are a logical choice [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/17\">",
"     17",
"    </a>",
"    ]. Because benzodiazepines provide no analgesia, opioids (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) may be needed to treat pain. Opioids also provide synergy and may decrease the amount of benzodiazepine required [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/18\">",
"     18",
"    </a>",
"    ]. Intermittent injections of sedative-analgesic agents are preferred, with continuous infusions reserved for patients who require repeated doses to achieve adequate sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/19\">",
"     19",
"    </a>",
"    ]. Occasionally, agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    may be useful alternatives, although the latter can be expensive, especially when used for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several articles highlight significant morbidity associated with excessive sedation. Strategies such as routinely waking patients each day [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/22\">",
"     22",
"    </a>",
"    ], using intermittent instead of continuous infusions of sedatives [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/23\">",
"     23",
"    </a>",
"    ], and following a sedation and analgesia protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/19\">",
"     19",
"    </a>",
"    ] may lead to important benefits such as decreased time on the ventilator and fewer nosocomial infections. The avoidance of excessive sedation is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link&amp;anchor=H16#H16\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\", section on 'Avoid excess sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using sedation scales such as the Richmond Agitation-Sedation Scale (RASS) may help clinicians meet sedation goals more effectively, decreasing the likelihood of over or under-sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/19,24\">",
"     19,24",
"    </a>",
"    ]. Most patients should be manageable with light sedation (eg, RASS of 0 or negative 1) although some patients with more severe lung injury or poor tolerance of mechanical ventilation may need to be sedated more deeply. Two studies found no evidence that increased sedation is required when patients are managed with low tidal volume as opposed to more traditional higher tidal volume ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that using no pharmacological sedation may be superior to using a continuous sedative infusion with daily interruption. In a single center study that enrolled patients requiring mechanical ventilation for more than 24 hours (including patients with ARDS), a protocol of no sedation was compared to the use of a continuous sedative infusion with daily interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients managed without sedation received intensive non-pharmacological support, such as verbal comforting and reassurance. The no sedation group spent more time off the ventilator and less time in the ICU than those managed with continuous sedative infusions that were interrupted daily. Similar studies in patients with ARDS need to be performed to determine whether a strategy of no sedation is a viable approach in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is widely recognized that neuromuscular blockade can have desirable effects (improves oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/28\">",
"     28",
"    </a>",
"    ]) and undesirable effects (prolonged neuromuscular weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/29\">",
"     29",
"    </a>",
"    ]) in patients with ARDS, the impact of these competing effects on patient-important outcomes has remained unclear. This uncertainty was addressed by a multicenter trial that randomly assigned 340 patients with ARDS to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    besylate or placebo by continuous infusion for 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/30\">",
"     30",
"    </a>",
"    ]. At the time of enrollment, all of the patients had been mechanically ventilated using low tidal volume ventilation and had a",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio of &lt;150 mmHg on a PEEP of &ge;5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O for less than 48 hours. Both groups were deeply sedated to a Ramsay sedation score of 6 (no response to glabellar tap). Patients treated with cisatracurium besylate had non-statistically significant lower crude 90-day, 28-day, hospital, and ICU mortality rates compared to the placebo group. Following a pre-specified statistical plan, the authors adjusted for baseline differences in the",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"     ,",
"    </span>",
"    SAPS II severity score, and plateau airway pressure, and found a statistically significant decrease in 90-day mortality in patients treated with cisatracurium besylate (HR 0.68, 95% CI 0.48-0.98). The beneficial effects on 90-day mortality were limited to patients who presented with a",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio of less than 120 mm Hg. Patients treated with cisatracurium besylate also had significantly more ventilator-free days during the first 28 and 90 days (defined as the number of days since successful weaning from mechanical ventilation) and were significantly less likely to experience barotrauma. There was no difference in the frequency of ICU-acquired neuromuscular weakness.",
"   </p>",
"   <p>",
"    We believe that these findings need to be replicated before neuromuscular blockade becomes part of the routine management of patients with early, severe ARDS. Until then, the body of evidence suggests that the administration of short-term (up to 48 hours) neuromuscular blockade to patients with ARDS who have severe gas exchange abnormalities (eg,",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    &le;120 mmHg) is probably safe and potentially beneficial. The neuromuscular blocking agents are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic management guided by a central venous catheter (CVC) has been compared to that guided by a pulmonary artery catheter (PAC) in patients with ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/7\">",
"     7",
"    </a>",
"    ]. In the trial, 1000 patients with ARDS were randomly assigned to receive a CVC or a PAC. There was no difference in mortality, lung function, ventilator-free days, organ failure free days, or ICU-free days at day 28. Rates of hypotension, dialysis, and vasopressor use were also the same in both groups. But, the PAC group had an approximately two-fold increase of catheter-related complications, predominantly arrhythmias. This suggests that the PAC should not be used routinely in patients with ARDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ARDS are intensely catabolic and benefit from nutritional support [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/31\">",
"     31",
"    </a>",
"    ]. If the gastrointestinal tract is available for nutritional intake, enteral feedings are preferred. Possible advantages of the enteral route include fewer intravascular infections, less GI bleeding because of gastric buffering, and preservation of the intestinal mucosal barrier, which in turn may decrease bacterial translocation across the gut. Overfeeding offers no nutritional advantage and should be avoided to prevent excessive carbon dioxide production. When patients are fed, it is essential that they be kept semirecumbent with their heads in the upright position to decrease the risk of ventilator-associated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glucose control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to glucose control in patients with ARDS is extrapolated from trials that enrolled patients with critical illness, including ARDS. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial (ie, ventilator-associated) pneumonia frequently complicates the course of ARDS. As an example, one prospective study of 30 patients with severe ARDS found that nosocomial pneumonia developed in 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/33\">",
"     33",
"    </a>",
"    ]. The first episode occurred at an average of 10 days after the onset of ARDS.",
"   </p>",
"   <p>",
"    Nosocomial pneumonia increases morbidity in ARDS, although the impact on mortality is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/34\">",
"     34",
"    </a>",
"    ]. Given the baseline radiographic abnormalities and frequent colonization by potential pathogens, it is difficult to diagnose pneumonia in patients with ARDS on the basis of clinical factors alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The misdiagnosis of pneumonia in patients with ARDS may have unfortunate consequences. Inappropriate treatment of patients without pneumonia promotes the emergence of organisms with antibiotic resistance, while a missed diagnosis may be lethal. The diagnosis of ventilator-associated pneumonia is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed, inappropriate, or inadequate antibiotic use is associated with poor outcome; therefore, it is essential to choose an initial antibiotic regimen sufficiently broad to cover likely infecting organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/36\">",
"     36",
"    </a>",
"    ]. Antibiotic choices should consider local sensitivity profiles, which may vary significantly from hospital to hospital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial pneumonia is difficult to prevent since patients with ARDS are frequently malnourished and immunosuppressed. In addition, normal airway defenses are bypassed by the endotracheal tube (ETT), and pulmonary edema is an excellent growth medium for bacteria. Despite widespread pulmonary infiltration by neutrophils, these cells offer poor protection against invading organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=see_link\">",
"     \"Endotracheal tube management and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of strategies have been proposed to decrease the likelihood of a patient developing nosocomial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/38\">",
"     38",
"    </a>",
"    ]. Some studies have suggested that selective decontamination of the digestive tract can decrease the risk of pneumonia. Unfortunately, evidence supporting this practice, particularly in the medical ICU population, is uncertain at best; in addition, the procedure raises the cost of ICU care and promotes the emergence of resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/39\">",
"     39",
"    </a>",
"    ]. Continuous subglottic aspiration may decrease infection by organisms occupying the digestive tract, but not by Pseudomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avoiding the supine position in mechanically ventilated patients, particularly those receiving enteral feedings, has been associated with a significant decrease in the rate of ventilator-associated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/32\">",
"     32",
"    </a>",
"    ]. Other important considerations include avoiding unnecessary antibiotics, careful attention to mouth care, weaning patients in a timely manner to decrease the duration of mechanical ventilation, avoiding excessive sedation, avoiding ventilator circuit changes, and routinely draining ventilator circuit condensate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary evidence initially suggested that closed tracheal suctioning systems might lower the incidence of ventilator-associated pneumonia (VAP). However, a more recent meta-analysis demonstrated that closed systems do not decrease the rate of VAP, mortality, or ICU length of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=see_link\">",
"     \"The ventilator circuit and ventilator-associated pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     DVT prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of DVT and pulmonary embolism (PE) in patients with ARDS is unknown, but the risk is certainly high. These patients often have multiple risk factors for venous thrombosis, including prolonged immobility, trauma, activation of the coagulation pathway, and predisposing illnesses, such as obesity and malignancy. Prevention of venous thromboembolic disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     GI prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring prolonged mechanical ventilation are at increased risk for gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/42\">",
"     42",
"    </a>",
"    ]. Prophylaxis against stress ulcers is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF HYPOXEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with ARDS are severely hypoxemic. Options available for improving arterial oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of high fractions of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      )",
"     </li>",
"     <li>",
"      Decrease oxygen consumption",
"     </li>",
"     <li>",
"      Improve oxygen delivery",
"     </li>",
"     <li>",
"      Manipulate mechanical ventilatory support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These options are most frequently applied in combination. Unfortunately, each modality is associated with an element of unquantifiable risk. As a result, the clinician must ultimately choose a strategy that provides adequate oxygenation (PaO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;55 to 80 mmHg) while minimizing the inevitable risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients require a high FiO",
"    <sub>",
"     2",
"    </sub>",
"    , especially early in ARDS when pulmonary edema is most severe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/43\">",
"     43",
"    </a>",
"    ]. Although high flow oxygen can be provided through a face mask, it is difficult to provide more than approximately 70 percent noninvasively because environmental air is entrained. By comparison, up to 100 percent oxygen is delivered easily when administered through an endotracheal tube.",
"   </p>",
"   <p>",
"    Almost all patients therefore require intubation and mechanical ventilation. During the peri-intubation period, 95 to 100 percent oxygen should be given to ensure an adequate SaO",
"    <sub>",
"     2",
"    </sub>",
"    . Because oxygen uptake may exceed replenishment in areas with low",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    ratios, some clinicians use slightly less than 100 percent oxygen (eg, 95 percent) in an attempt to prevent absorptive atelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/44\">",
"     44",
"    </a>",
"    ]. Once well established, absorptive atelectasis is not rapidly reversed by reduction of FiO",
"    <sub>",
"     2",
"    </sub>",
"    to maintenance levels, emphasizing the desirability of rapid downward titration of FiO",
"    <sub>",
"     2",
"    </sub>",
"    to the lowest fraction necessary to maintain an SaO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the risk of high FiO",
"    <sub>",
"     2",
"    </sub>",
"    supplementation has not been studied specifically in patients with ARDS, it is probably significant. Studies in animals and normal humans reveal that high concentrations of oxygen damage the lung within hours, in part by forming toxic oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. The specific threshold for oxygen toxicity is unknown but appears to begin above 50 percent, and the risk rises as concentrations approach 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/49\">",
"     49",
"    </a>",
"    ]. As a result, the FiO",
"    <sub>",
"     2",
"    </sub>",
"    should be decreased to the 50 to 60 percent range as soon as safely possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical ventilation strategies in patients with ARDS, including those that may allow a decrease in the FiO",
"    <sub>",
"     2",
"    </sub>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although increased vascular permeability is the primary cause of pulmonary edema in early ARDS, the quantity of edema formed depends directly upon hydrostatic pressure, since oncotic forces are less capable of retaining fluid within the capillaries (",
"    <a class=\"graphic graphic_figure graphicRef73684 graphicRef69933 graphicRef73443 graphicRef61194 \" href=\"UTD.htm?38/12/39111\">",
"     figure 2A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. As a result, pulmonary edema is more likely to develop in ARDS than in normals for any given pulmonary capillary hydrostatic pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, even in patients who are not volume overloaded, a strategy of conservative fluid management may help patients by reducing edema formation. This was best illustrated by a trial in which 1000 patients with established ARDS were randomly assigned to either a conservative or a liberal strategy of fluid management for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients assigned to the conservative group were managed with a fluid strategy that targeted a CVP &lt;4 mmHg or a pulmonary artery occlusion pressure (PAOP) &lt;8 mmHg. Patients managed with the liberal strategy targeted a CVP of 10 to 14 mmHg or a PAOP of 14 to 18 mmHg. The mean cumulative fluid balance was -136 mL in the conservative strategy group and +6992 mL in the liberal strategy group. The conservative strategy improved the oxygenation index and lung injury score, while increasing ventilator-free days (15 versus 12 days) and ICU-free days (13 versus 11 days). The 60 day mortality rate was unaltered by the fluid management strategy. Despite clearly identified CVP and PAOP goals, mean CVP and PAOP remained well above the target goals in the conservative management group, suggesting that a CVP &lt;4 mmHg or a PAOP &lt;8 mmHg is difficult to achieve safely with the strategies outlined in this population.",
"   </p>",
"   <p>",
"    Given the clinical benefits demonstrated in this trial, we believe that a conservative strategy of fluid management is warranted in patients with ARDS, as long as hypotension and organ hypoperfusion can be avoided. It is reasonable to target a central venous pressure of &lt;4 mmHg or a pulmonary artery occlusion pressure &lt;8 mmHg; however, it should be recognized that such goals may be difficult to achieve. Preliminary data suggests that combination therapy with albumin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    may improve fluid balance, oxygenation, and hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ancillary measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need to avoid oxygen toxicity justifies the consideration of a variety of other techniques designed to improve SaO",
"    <sub>",
"     2",
"    </sub>",
"    , including diuresis, prone positioning, and strategies to decrease oxygen consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prone positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prone positioning improves oxygenation in the majority of patients with ARDS. Individual studies have not shown a survival advantage, but a meta-analysis suggested a possible survival advantage among patients with the most severe hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/27\">",
"     27",
"    </a>",
"    ]. The physiologic effects, efficacy, and application of prone ventilation are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39078?source=see_link\">",
"     \"Prone ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Decrease oxygen consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;In diseases with severe pulmonary shunting, increasing the saturation of mixed venous blood (SvO",
"    <sub>",
"     2",
"    </sub>",
"    ) may increase the SaO",
"    <sub>",
"     2",
"    </sub>",
"    . Therapies that decrease oxygen consumption may improve SvO",
"    <sub>",
"     2",
"    </sub>",
"    (and SaO",
"    <sub>",
"     2",
"    </sub>",
"    subsequently) by decreasing the amount of oxygen extracted from the blood. Common causes of increased oxygen consumption include fever, anxiety and pain, and use of respiratory muscles; therefore, arterial saturation may improve after treatment with anti-pyretics, sedatives, analgesics, or paralytics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/28,54\">",
"     28,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Increase oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen delivery is determined by the following formula:",
"   </p>",
"   <p>",
"    &nbsp;DO",
"    <sub>",
"     2",
"    </sub>",
"    = 10 x CO x (1.34 x Hgb x SaO",
"    <sub>",
"     2",
"    </sub>",
"    + 0.003 x PaO",
"    <sub>",
"     2",
"    </sub>",
"    )",
"   </p>",
"   <p>",
"    where DO",
"    <sub>",
"     2",
"    </sub>",
"    is oxygen delivered, CO is cardiac output, Hgb is hemoglobin concentration, SaO",
"    <sub>",
"     2",
"    </sub>",
"    is the arterial oxygen saturation, and PaO",
"    <sub>",
"     2",
"    </sub>",
"    is the partial pressure of oxygen in arterial blood. As a result, in addition to low SaO",
"    <sub>",
"     2",
"    </sub>",
"    , DO",
"    <sub>",
"     2",
"    </sub>",
"    may be decreased by a low Hgb and a low CO. In turn, a low DO",
"    <sub>",
"     2",
"    </sub>",
"    may decrease SvO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    In anemic patients, attempts to increase the hemoglobin concentration may be useful, but exceeding 9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is unlikely to increase benefit. One multicenter trial randomized 838 critically ill patients to a \"restrictive\" transfusion strategy to maintain the hemoglobin concentration between 7 and 9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    or to a \"liberal\" transfusion strategy to maintain it between 10 and 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/55\">",
"     55",
"    </a>",
"    ]. The 30-day mortality rates of the two groups did not differ significantly, and patients randomized to the restrictive strategy had a lower mortality rate during the period of hospitalization (22 versus 28 percent; p = 0.05).",
"   </p>",
"   <p>",
"    More recent studies suggest that transfusion of packed red blood cells may increase a patient's risk of developing ARDS and dying once ARDS is established [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/56\">",
"     56",
"    </a>",
"    ]. For this reason, we suggest restricting transfusion of packed red blood cells in most ARDS patients, unless the hemoglobin falls below 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or if there are other compelling reasons to justify transfusions.",
"   </p>",
"   <p>",
"    Cardiac output may be augmented by raising filling pressures if they are low (if pulmonary edema is not exacerbated) or by using inotropic agents. However, raising oxygen delivery to supernormal levels is not clinically useful and may be harmful in some circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/10,57,58\">",
"     10,57,58",
"    </a>",
"    ]. One prospective study, for example, randomized 100 patients with a variety of critical illnesses to either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    or placebo if volume expansion alone failed to achieve a boost in oxygen delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9065/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients in the control group received dobutamine only if their cardiac index was below 2.8 liters per minute per square meter. Despite achieving higher oxygen delivery and cardiac indices, active therapy resulted in a higher mortality (54 versus 34 percent for the control group).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"       \"Patient information: Adult respiratory distress syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the mid to late 1990s show a decrease in mortality from the acute respiratory distress syndrome (ARDS). The decrease in mortality is probably due to several factors, including improved supportive care and a more thoughtful approach to mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key components of supportive care include intelligent use of sedatives and neuromuscular blockade, careful hemodynamic management, nutritional support, control of blood glucose, expeditious evaluation and treatment of nosocomial pneumonia, and prophylaxis against deep vein thrombosis (DVT) and gastrointestinal (GI) bleeding. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hypoxic respiratory failure may benefit from strategies that decrease oxygen utilization, such as antipyretics to control fever and sedatives to control agitation. Occasionally, neuromuscular blockade is required, particularly when asynchrony with the ventilator persists despite adequate sedation. For patients with particularly severe gas exchange abnormalities (eg,",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &le;120 mmHg), up to 48 hours of neuromuscular blockade is probably safe and potentially beneficial, but requires additional investigation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sedation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Paralysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilator-associated pneumonia is a frequent complication of ARDS. When initiating therapy, empiric antibiotics coverage should be sufficiently broad to target all likely pathogens pending the results of sensitivity testing. Strategies that may lower the risk of ventilator-associated pneumonia include avoiding all of the following: the supine position, excess sedation, unnecessary antibiotics, and unnecessary ventilator circuit changes. Additional strategies include providing good mouth care, weaning patients from the ventilator in a timely manner, and perhaps use of continuous subglottic aspiration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nosocomial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data suggest that a conservative fluid management strategy that aims to minimize or eliminate positive fluid balance &mdash; for example, by aiming for a CVP &lt;4 mmHg or a PAOP &lt;8 mmHg &mdash; offers clinical advantages, including improved oxygenation, increased ventilator-free days, and ICU-free days. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fluid management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While blood transfusion and inotropes may augment oxygen delivery, most data caution against indiscriminate use of these strategies. For most patients, packed red blood cells can be withheld until the hemoglobin concentration drops below 7",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      unless there are alternative reasons for transfusion. Similarly, there is no evidence that inotropes benefit ARDS patients with a normal cardiac function. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ancillary measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/1\">",
"      Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/2\">",
"      Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/3\">",
"      Stapleton RD, Wang BM, Hudson LD, et al. Causes and timing of death in patients with ARDS. Chest 2005; 128:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/4\">",
"      Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/5\">",
"      Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008; 133:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/6\">",
"      Erickson SE, Martin GS, Davis JL, et al. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med 2009; 37:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/7\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/8\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/9\">",
"      Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med 2009; 179:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/10\">",
"      Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/11\">",
"      Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/12\">",
"      Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/13\">",
"      Suchyta MR, Clemmer TP, Elliott CG, et al. The adult respiratory distress syndrome. A report of survival and modifying factors. Chest 1992; 101:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/14\">",
"      Doyle RL, Szaflarski N, Modin GW, et al. Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 1995; 152:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/15\">",
"      Hansen-Flaschen J. Improving patient tolerance of mechanical ventilation. Challenges ahead. Crit Care Clin 1994; 10:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/16\">",
"      Swinamer DL, Phang PT, Jones RL, et al. Effect of routine administration of analgesia on energy expenditure in critically ill patients. Chest 1988; 93:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/17\">",
"      Cernaianu AC, DelRossi AJ, Flum DR, et al. Lorazepam and midazolam in the intensive care unit: a randomized, prospective, multicenter study of hemodynamics, oxygen transport, efficacy, and cost. Crit Care Med 1996; 24:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/18\">",
"      Stoltzfus DP. Advantages and disadvantages of combining sedative agents. Crit Care Clin 1995; 11:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/19\">",
"      Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/20\">",
"      Mirenda J, Broyles G. Propofol as used for sedation in the ICU. Chest 1995; 108:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/21\">",
"      Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/22\">",
"      Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/23\">",
"      Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/24\">",
"      Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/25\">",
"      Cheng IW, Eisner MD, Thompson BT, et al. Acute effects of tidal volume strategy on hemodynamics, fluid balance, and sedation in acute lung injury. Crit Care Med 2005; 33:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/26\">",
"      Kahn JM, Andersson L, Karir V, et al. Low tidal volume ventilation does not increase sedation use in patients with acute lung injury. Crit Care Med 2005; 33:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/27\">",
"      Sud S, Friedrich JO, Taccone P, et al. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med 2010; 36:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/28\">",
"      Gainnier M, Roch A, Forel JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004; 32:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/29\">",
"      Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/30\">",
"      Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/31\">",
"      Cerra FB, Benitez MR, Blackburn GL, et al. Applied nutrition in ICU patients. A consensus statement of the American College of Chest Physicians. Chest 1997; 111:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/32\">",
"      Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999; 354:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/33\">",
"      Delclaux C, Roupie E, Blot F, et al. Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis. Am J Respir Crit Care Med 1997; 156:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/34\">",
"      Sutherland KR, Steinberg KP, Maunder RJ, et al. Pulmonary infection during the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/35\">",
"      Fagon JY, Chastre J, Hance AJ, et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993; 103:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/36\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/37\">",
"      Lin CC, Lin CY. Enhanced chemiluminescence with decreased antibody-dependent cellular cytotoxicity of human alveolar neutrophil in patients with adult respiratory distress syndrome. Respiration 1992; 59:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/38\">",
"      Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/39\">",
"      Verwaest C, Verhaegen J, Ferdinande P, et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med 1997; 25:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/40\">",
"      Vall&eacute;s J, Artigas A, Rello J, et al. Continuous aspiration of subglottic secretions in preventing ventilator-associated pneumonia. Ann Intern Med 1995; 122:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/41\">",
"      Siempos II, Vardakas KZ, Falagas ME. Closed tracheal suction systems for prevention of ventilator-associated pneumonia. Br J Anaesth 2008; 100:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/42\">",
"      Schuster DP, Rowley H, Feinstein S, et al. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984; 76:623.",
"     </a>",
"    </li>",
"    <li>",
"     Hasleton PS. Adult respiratory distress syndrome. In: Spencer's Pathology of the Lung, Hasleton PS (Ed), McGraw Hill, New York 1996. p.375.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/44\">",
"      Wagner PD, Laravuso RB, Uhl RR, West JB. Continuous distributions of ventilation-perfusion ratios in normal subjects breathing air and 100 per cent O2. J Clin Invest 1974; 54:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/45\">",
"      Santos C, Ferrer M, Roca J, et al. Pulmonary gas exchange response to oxygen breathing in acute lung injury. Am J Respir Crit Care Med 2000; 161:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/46\">",
"      Sackner MA, Landa J, Hirsch J, Zapata A. Pulmonary effects of oxygen breathing. A 6-hour study in normal men. Ann Intern Med 1975; 82:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/47\">",
"      Comroe, JH, Dripps, RD, Dumke, PR, et al. The effect of inhalation of high concentrations of oxygen for 24 hours on normal men at sea level and at a simulated altitude of 18,000. JAMA 1945; 128:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/48\">",
"      Freeman BA, Crapo JD. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 1981; 256:10986.",
"     </a>",
"    </li>",
"    <li>",
"     Lodato RF. Oxygen toxicity. In: Principles and Practice of Mechanical Ventilation, Tobin MJ (Ed), McGraw-Hill Inc, New York 1994. p.837.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/50\">",
"      Mitchell JP, Schuller D, Calandrino FS, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis 1992; 145:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/51\">",
"      Simmons RS, Berdine GG, Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 135:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/52\">",
"      Humphrey H, Hall J, Sznajder I, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990; 97:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/53\">",
"      Martin GS, Mangialardi RJ, Wheeler AP, et al. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med 2002; 30:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/54\">",
"      Suzuki S, Hotchkiss JR, Takahashi T, et al. Effect of core body temperature on ventilator-induced lung injury. Crit Care Med 2004; 32:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/55\">",
"      H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/56\">",
"      Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005; 33:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/57\">",
"      Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9065/abstract/58\">",
"      Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1641 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9065=[""].join("\n");
var outline_f8_54_9065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nutritional support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glucose control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DVT prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GI prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT OF HYPOXEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ancillary measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prone positioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Decrease oxygen consumption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Increase oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1641|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/11/3263\" title=\"figure 1\">",
"      ARDS mortality trend",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35502\" title=\"figure 2A\">",
"      Protective mechanisms in edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/15/8447\" title=\"figure 2B\">",
"      Early development edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/43/23231\" title=\"figure 2C\">",
"      Late development edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/20/44367\" title=\"figure 2D\">",
"      Alveolar edema development",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=related_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39078?source=related_link\">",
"      Prone ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=related_link\">",
"      The ventilator circuit and ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_54_9066="Acute chest syndrome in adults with sickle cell disease";
var content_f8_54_9066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute chest syndrome in adults with sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Joshua J Field, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Michael R DeBaun, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/54/9066/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/54/9066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H955280\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute chest syndrome (ACS) is a leading cause of death for patients with sickle cell disease (SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Defined as a new radiodensity on chest radiograph accompanied by fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory symptoms, ACS in adults with SCD requires prompt management to prevent clinical deterioration and death [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACS in adults with sickle cell disease will be discussed here. ACS in children and adolescents with SCD is discussed separately, although management is largely the same in both settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=see_link\">",
"     \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239481\">",
"    <span class=\"h1\">",
"     DIFFERENCES BETWEEN ACS IN CHILDREN AND ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of ACS events is categorized as mild, moderate and severe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/3\">",
"     3",
"    </a>",
"    ]; the definition of ACS and the severity categories apply equally to children and adults. (See",
"    <a class=\"local\" href=\"#H13239723\">",
"     'Diagnosis of ACS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A key difference in the clinical presentation of ACS between children and adults with SCD is the greater disease severity and a higher mortality rate in adults, largely due to a higher incidence of bone marrow and fat emboli in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In adults with SCD, up to 77 percent of ACS episodes are the result of bone marrow or fat emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/6\">",
"     6",
"    </a>",
"    ]; in children, the proportion is much lower [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differing etiologies and clinical course of ACS episodes underscore the notion that the definition of ACS (a new radiodensity on chest radiograph with respiratory symptoms) captures a",
"    <strong>",
"     non-specific clinical endpoint",
"    </strong>",
"    that includes different underlying pathogenic processes. As examples, the broad definition of ACS does not differentiate between a patient with SCD who presents with fever, increased respiratory effort, and a new radiodensity due to bronchiolitis requiring a brief inpatient admission (a more common scenario in children) from ACS with intra-pulmonary vasoocclusion and respiratory failure due to fat emboli requiring management in the intensive care unit (a more common scenario in adults).",
"   </p>",
"   <p>",
"    Although the management of ACS episodes is largely the same in adults and children with SCD, the higher rate of severe ACS episodes in adults should prompt a lower threshold for the use of red blood cell transfusion therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955287\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the Cooperative Study of Sickle Cell Disease (CSSCD), the largest natural history study of SCD that includes both adults and children, approximately 50 percent of patients with SCD will have an episode of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/8\">",
"     8",
"    </a>",
"    ]. Seventy-eight percent of these episodes of ACS are associated with a vasoocclusive pain crisis, usually occurring within 48 to 72 hours after hospital admission for pain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence rate of ACS is highest at two to four years of age among children with homozygous sickle cell disease (HbSS), with a rate of 25.3 per 100 patient-years, and decreases to 8.78 per 100 patient-years in adults &gt;20 years of age with HbSS [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although ACS can occur in any sickle cell disease phenotype, including HbS-hereditary persistence of fetal hemoglobin, individuals with HbSS have the highest rate of ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar to children, the incidence rate of ACS for patients with HbSC or HbS&beta;",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia",
"      <sup>",
"      </sup>",
"      is significantly less than that in HbSS or HbS&beta;",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia, with rates of 1.95 and 3.27 per 100 patient-years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Risk factors for ACS among adults with HbSS &gt;20 years old include increased white blood cell count, higher hemoglobin levels, and lower fetal hemoglobin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/8\">",
"       8",
"      </a>",
"      ]. Smoking and vasoocclusive pain events have also been identified as risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adults with SCD and a higher incidence rate of ACS episodes also have an increased risk of death [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/1\">",
"       1",
"      </a>",
"      ]. The rate of death per ACS episode is 4.3 percent in adults with SCD compared with a rate of 1.1 percent in children [",
"      <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239503\">",
"    <span class=\"h2\">",
"     Repeated episodes of ACS and interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that repeated ACS episodes are associated with the development of interstitial lung disease (ILD, previously referred to as chronic sickle cell lung disease) and in many cases attendant pulmonary hypertension. In a case-control study that compared 28 patients with SCD and ILD (median age at diagnosis of ILD of 25 years) with 34 matched controls without ILD, the number of prior ACS episodes was found to be the most significant risk factor for the development this complication (RR 16.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course of the patients with ILD in this study was characterized by a progressive worsening of pulmonary fibrosis on chest radiograph, hypoxia, a restrictive lung pattern on pulmonary function testing, and pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/11\">",
"     11",
"    </a>",
"    ]. Those with ILD also had an increased risk of death, with a median time from diagnosis of this complication to death of 5.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is most likely that the pathogenesis of ILD among patients with SCD is multi-factorial, involving the contribution of more etiologies than ACS episodes alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3817698\">",
"    <span class=\"h2\">",
"     Repeated episodes of ACS and pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between ACS and the development of pulmonary hypertension documented by right heart catheterization has not been established. In the largest study to date of 195 adults with SCD, elevated tricuspid jet velocity &ge;2.5",
"    <span class=\"nowrap\">",
"     meters/second,",
"    </span>",
"    a proxy for an elevated pulmonary artery pressure, has not been associated with repeated ACS episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contribution of ACS, if any, to the development of pulmonary hypertension is difficult to discern, especially when different definitions for pulmonary hypertension have been used across studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955301\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large cohort studies (National Acute Chest Syndrome Study Group [NACSSG] [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ] and CSSCD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]) have best defined the clinical presentation and outcomes of ACS in adults and children with SCD, although the majority of subjects in both cohorts consisted of children.",
"   </p>",
"   <p>",
"    The NACSSG examined a cohort of 538 adults and children with SCD and 671 episodes of ACS in order to evaluate causes and outcomes of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ]. Significant differences in etiology and clinical course of ACS were found when adults &ge;20 years were compared with children zero to 19 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults were more likely to present with complaints of chest pain (55 versus 41 percent), pain in the arms and legs (59 versus 30 percent), rib and sternal pain (30 versus 18 percent), and shortness of breath (58 versus 36 percent) than were children.",
"     </li>",
"     <li>",
"      Episodes of ACS in adults were more likely to be complicating vaso-occlusive pain episodes compared with children with SCD (82 versus 58 percent); adults commonly had neurological findings during these ACS events (22 versus 8 percent).",
"     </li>",
"     <li>",
"      The clinical course of adults versus children with ACS was also very different. Adults were more likely to require mechanical ventilation (22 versus 10 percent), have a prolonged hospital stay (13 versus 10 days), and have a greater risk of death (9 versus 1 percent) compared with children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from the Cooperative Study of Sickle Cell Disease (CSCCD) examined 939 children and adults with SCD who had 1722 episodes of ACS and found that adults with SCD were more likely than children to present with chest pain (84 versus 41 percent) and shortness of breath (47 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/7\">",
"     7",
"    </a>",
"    ]. The radiographic findings also differed by age, as adults were more likely than children to have multilobe involvement of infiltrates (36 versus 24 percent). Additionally, adults were more likely to have pain preceding the ACS event (50 versus 11 percent) whereas children were more likely to have fever (64 versus 85 percent).",
"   </p>",
"   <p>",
"    Taken together, the findings from these two studies show that ACS episodes in adults with SCD are often preceded by a vasoocclusive pain episode, present with chest, arm, and leg pain consistent with a pain crisis, and follow a much more severe clinical course, often requiring mechanical ventilation, and sometimes resulting in death. These data also underscore the importance of applying evidence generated from adults as opposed to children with SCD when making treatment decisions about ACS in an adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955308\">",
"    <span class=\"h1\">",
"     BONE MARROW AND FAT EMBOLI AS A CAUSE OF ACS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239548\">",
"    <span class=\"h2\">",
"     Clinical and laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports and case series have documented fat embolism as a cause for 44 to 77 percent of ACS episodes in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/4,6,14-22\">",
"     4,6,14-22",
"    </a>",
"    ]. Despite the challenging diagnosis of fat emboli as the initiating cause of ACS, significant evidence including laboratory findings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/20\">",
"     20",
"    </a>",
"    ], post-mortem evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/22\">",
"     22",
"    </a>",
"    ], imaging of the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/16\">",
"     16",
"    </a>",
"    ], and bone marrow biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/19\">",
"     19",
"    </a>",
"    ] support this unique diagnosis. However, since testing for fat emboli requires bronchoscopy and is not performed routinely, the true incidence of fat emboli in patients with ACS is not known.",
"   </p>",
"   <p>",
"    Bone marrow aspiration showing bone marrow necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/15,19\">",
"     15,19",
"    </a>",
"    ] and bone marrow imaging showing recent bone marrow infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/16\">",
"     16",
"    </a>",
"    ] provided preliminary evidence for a causative role of fat emboli in ACS. Two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/6,20\">",
"     6,20",
"    </a>",
"    ] and a follow-up study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/17\">",
"     17",
"    </a>",
"    ] significantly added to this evidence by performing bronchoalveolar lavage during ACS episodes and demonstrating the presence of fat in alveolar macrophages.",
"   </p>",
"   <p>",
"    In a study of 20 adults with SCD and ACS, bronchoalveolar lavage was performed to examine for the presence of fat-containing alveolar macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/6\">",
"     6",
"    </a>",
"    ]. Using a cut-off of &gt;5 percent fat-containing alveolar macrophages, 60 percent of ACS cases in adults with SCD were associated with fat emboli. Furthermore, 92 percent of the cases demonstrating fat-containing alveolar macrophages showed some evidence of bone marrow infarction on MRI or radioisotopic bone imaging.",
"   </p>",
"   <p>",
"    A follow-up study of adults with SCD evaluated whether induced sputum could reliably detect fat-containing alveolar macrophages when compared with bronchoalveolar lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/17\">",
"     17",
"    </a>",
"    ]. A significant correlation was found between induced sputum and bronchoalveolar lavage for detecting fat-containing macrophages. Similar to prior studies, adults with evidence of fat emboli were more likely to have signs and symptoms consistent with bone marrow infarction, including pain, neurological symptoms, and a lower platelet count.",
"   </p>",
"   <p>",
"    Lipemia retinalis and petechiae are not commonly seen in fat emboli in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]; if observed, however, these findings would be consistent with the clinical syndrome of fat emboli. ACS etiologies other than vasoocclusion may also be associated with bone marrow necrosis and fat emboli, such as parvovirus B19 infection, and may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twenty-seven children with SCD versus 43 controls underwent bronchoscopy with bronchoalveolar lavage to determine whether pulmonary fat emboli could also be detected in the lungs of children with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/20\">",
"     20",
"    </a>",
"    ]. Among the 27 children with SCD, 12 (44 percent) demonstrated evidence of pulmonary macrophages with intracellular fat while no control subject had pulmonary fat emboli. Consistent with the hypothesis that the pulmonary fat emboli are generated during a vasoocclusive crisis and contribute to a unique clinical presentation, all of the SCD subjects with pulmonary fat emboli presented with pain, 11 of 12 reported chest pain, and 6 of 12 had neurological symptoms. In comparison, only 6 of 15 patients who were negative for pulmonary fat emboli had pain or chest pain and no subject displayed neurological findings. The patients with pulmonary fat emboli were more likely to have more lung segments involved with infiltrate, have lower oxygen saturation, develop respiratory distress, and have a longer hospital stay.",
"   </p>",
"   <p>",
"    Laboratory findings in patients with pulmonary fat emboli on bronchoscopy compared with those without this finding, showed lower hemoglobin levels, lower platelet counts, and increased numbers of circulating nucleated red blood cells. These latter laboratory tests reflect the presence of bone marrow necrosis underlying the generation of bone marrow and fat emboli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of bone marrow aspirate smears\", section on 'Bone marrow necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955315\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoocclusion within the pulmonary microvasculature is the basis for ACS pathophysiology. Etiologies for ACS either trigger vasoocclusion (eg, infection, asthma, hypoventilation) or are a result of vasoocclusion (eg, bone marrow and fat emboli) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. These etiologies can occur together; once intra-pulmonary vasoocclusion is initiated, it is propagated by hypoxia, inflammation, and acidosis.",
"   </p>",
"   <p>",
"    Bone marrow ischemia and necrosis, characteristic of SCD vasoocclusive episodes, cause the release of bone marrow and fat into the venous circulation where they primarily affect the lungs and the central nervous system by mechanically obstructing the vasculature and promoting a pro-inflammatory state [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/4\">",
"     4",
"    </a>",
"    ]. Inflammation associated with fat emboli is likely due to the presence of free fatty acids converted from neutral fat by secretory phospholipase A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/4\">",
"     4",
"    </a>",
"    ]. Free fatty acids are highly pro-inflammatory and more likely to cause tissue injury than neutral fats [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/27\">",
"     27",
"    </a>",
"    ]. Hypoxemia and inflammation associated with bone marrow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fat embolism promote further vasoocclusion, creating a vicious cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239555\">",
"    <span class=\"h3\">",
"     Association with the multi-organ failure syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow necrosis with attendant bone marrow and fat emboli is also thought to contribute to the etiology of acute multi-organ failure syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. There is significant overlap between the clinical presentation of severe ACS episodes due to fat emboli in adults with SCD and multi-organ failure syndrome.",
"   </p>",
"   <p>",
"    Acute multi-organ failure syndrome is characterized by acute dysfunction of the lung, liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    kidney (dysfunction of at least two of these three organs are required to meet the definition) occurring during a vaso-occlusive pain episode [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/28\">",
"     28",
"    </a>",
"    ]. Fever, confusion, decreased hemoglobin levels and decreased platelet counts are also frequently present during acute multi-organ failure syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/28\">",
"     28",
"    </a>",
"    ]. Since episodes of ACS associated with fat emboli are often characterized by infiltrates, hypoxia, confusion, and thrombocytopenia occurring during a painful vaso-occlusive episode, these ACS events likely represent the same underlying etiology of acute multi-system organ failure syndrome (bone marrow and fat emboli), with the predominant organ affected being the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955322\">",
"    <span class=\"h1\">",
"     OTHER ETIOLOGIES OF ACS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239577\">",
"    <span class=\"h2\">",
"     Infection and asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection and asthma, common causes of ACS in children with SCD, also occur in adults, albeit with a lower incidence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5,7,29,30\">",
"     5,7,29,30",
"    </a>",
"    ]. The NACSSG was largely comprised of children with SCD, but did include 128 adults &gt;20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5,29,30\">",
"     5,29,30",
"    </a>",
"    ]. The most common organisms associated with ACS events identified in the study were atypical bacteria and respiratory syncytial virus. Evidence for",
"    <em>",
"     Mycoplasma pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     Mycoplasma hominis",
"    </em>",
"    and",
"    <em>",
"     Chlamydia pneumoniae",
"    </em>",
"    as an etiology of ACS was found in a minority of adults &gt;20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ]. Of these organisms,",
"    <em>",
"     Chlamydia pneumoniae",
"    </em>",
"    was found more commonly in adolescents and young adults (median age 18 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ]. Similar to the lower incidence rate of infection reported in adults with ACS, data from the CSSCD reported wheezing as a presenting symptom and sign in only 13 and 8 percent of adults &gt;20 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239584\">",
"    <span class=\"h2\">",
"     Compromised ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-infectious causes of ACS in adults with SCD also include etiologies that compromise ventilation, such as over-sedation or the presence of bone infarcts involving the ribs, sternum, or vertebrae that predispose to poor inspiratory effort [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239591\">",
"    <span class=\"h2\">",
"     Pulmonary thrombi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary thrombi have been reported in autopsy studies of adult patients with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. Although there have been reports of pulmonary emboli secondary to deep venous thrombosis associated with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ], in many cases these thrombi within the pulmonary vasculature contain sickle erythrocytes suggestive of",
"    <em>",
"     in situ",
"    </em>",
"    thrombi related to vasoocclusion rather than emboli originating from deep veins [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H13#H13\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239723\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying definitions for ACS have been used in the studies that define the epidemiology, clinical presentation, risks, and outcomes of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5,7,8,38-40\">",
"     5,7,8,38-40",
"    </a>",
"    ]. A common thread among all available definitions is that they define an acute illness in SCD characterized by a new radiodensity and respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5,7,8,38-40\">",
"     5,7,8,38-40",
"    </a>",
"    ]. Problematic for clinicians and patients alike is that an infiltrate and fever in an adult with SCD may be diagnosed either as ACS or pneumonia, depending on the practitioner [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5,7,8,38-40\">",
"     5,7,8,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our recommended diagnostic evaluation for all adults with SCD who have a clinical presentation concerning for ACS includes an electrocardiogram, complete blood count with white blood cell differential, reticulocyte count, AP and lateral chest radiograph, and blood and sputum cultures. Additional testing, including a CT of the chest to evaluate for pulmonary embolus or serum troponin to evaluate for myocardial damage, should be obtained on a case-by-case basis depending on clinical suspicion and prior history. Bronchoscopy with bronchoalveolar lavage is typically performed in refractory or atypical cases.",
"   </p>",
"   <p>",
"    For this review, we have chosen to present the latest consensus definition of ACS that provides the most sensitive and complete set of clinical parameters that define ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928837\">",
"    <span class=\"h2\">",
"     Diagnostic criteria for ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACS is defined as radiographic evidence of consolidation: a new segmental (involving at least one complete segment) radiographic pulmonary infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/3\">",
"     3",
"    </a>",
"    ],",
"    <strong>",
"     AND",
"    </strong>",
"    at least one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature &ge;38.5&deg;C",
"     </li>",
"     <li>",
"      &gt;2 percent decrease in SpO",
"      <sub>",
"       2",
"      </sub>",
"      (O",
"      <sub>",
"       2",
"      </sub>",
"      saturation) from a documented steady-state value on room air (FiO",
"      <sub>",
"       2",
"      </sub>",
"      = 0.21)",
"     </li>",
"     <li>",
"      PaO2 &lt;60 mmHg",
"     </li>",
"     <li>",
"      Tachypnea (per age-adjusted normal)",
"     </li>",
"     <li>",
"      Intercostal retractions, nasal flaring, or use of accessory muscles of respiration",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Cough",
"     </li>",
"     <li>",
"      Wheezing",
"     </li>",
"     <li>",
"      R&acirc;les",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of importance, the presence of pneumonia can formally be considered as meeting the criteria for ACS, since the two cannot be reliably distinguished from one another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928844\">",
"    <span class=\"h2\">",
"     ACS severity index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severity of ACS is considered mild, moderate, severe, or very severe, as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928852\">",
"    <span class=\"h3\">",
"     Mild ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meets the diagnostic criteria for ACS plus",
"    <strong>",
"     ALL",
"    </strong>",
"    of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transcutaneous oxygen saturation &gt;90 percent on room air (FiO",
"      <sub>",
"       2",
"      </sub>",
"      = 0.21)",
"     </li>",
"     <li>",
"      Segmental or lobar infiltrates that involve no more than one lobe by chest radiography",
"     </li>",
"     <li>",
"      Responsive to simple transfusion of no more than 2 units of red blood cells (or 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of packed RBCs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928867\">",
"    <span class=\"h3\">",
"     Moderate ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meets the diagnostic criteria for ACS plus",
"    <strong>",
"     ALL",
"    </strong>",
"    of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transcutaneous oxygen saturation &ge;85 percent on room air (FiO",
"      <sub>",
"       2",
"      </sub>",
"      = 0.21)",
"     </li>",
"     <li>",
"      Segmental or lobar infiltrates that involve no more than two lobes by chest radiography",
"     </li>",
"     <li>",
"      Responsive to transfusion of &ge;3 units of red cells (or &gt;20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      packed RBCs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928882\">",
"    <span class=\"h3\">",
"     Severe ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meets the diagnostic criteria for ACS plus",
"    <strong>",
"     one or more",
"    </strong>",
"    of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory failure present (PaO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;60 mmHg or PCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;50 mmHg)",
"     </li>",
"     <li>",
"      Mechanical ventilatory support required",
"     </li>",
"     <li>",
"      Transcutaneous oxygen saturation &lt;85 percent on room air or &le;90 percent despite maximal supplemental O",
"      <sub>",
"       2",
"      </sub>",
"     </li>",
"     <li>",
"      Segmental or lobar infiltrates that involve three or more lobes by chest radiography",
"     </li>",
"     <li>",
"      Requiring transfusion or exchange transfusion of RBCs to achieve hemoglobin A levels &ge;70 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15928897\">",
"    <span class=\"h3\">",
"     Very severe ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute respiratory distress syndrome (ARDS) present or sudden, life-threatening lung failure. ARDS is defined by the following three criteria of the American-European Consensus Conference and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute onset of bilateral infiltrates on chest radiography",
"     </li>",
"     <li>",
"      Pulmonary artery wedge pressure &lt;19 mmHg or the absence of clinical evidence of left atrial hypertension",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &le;200 regardless of positive end expiratory pressure (PEEP) level",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955329\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an adult with SCD presents with symptoms of shortness of breath and chest pain, other life-threatening diagnoses in addition to ACS have to be considered, including pulmonary embolus, acute coronary syndrome, and pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239970\">",
"    <span class=\"h2\">",
"     Pulmonary embolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary emboli originating from the deep veins of the lower extremities are challenging to diagnose in the setting of ACS, as they are difficult to distinguish from",
"    <em>",
"     in situ",
"    </em>",
"    thrombi or bone marrow or fat emboli in the pulmonary vasculature secondary to sickle cell vasoocclusion.",
"    <em>",
"     In situ",
"    </em>",
"    thrombi, bone marrow, or fat emboli are expected to be present during ACS episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/14,36,41\">",
"     14,36,41",
"    </a>",
"    ] and, in comparison to pulmonary emboli associated with deep venous thrombosis, do not require or respond to anti-coagulation; transfusion of red cells to reduce vasoocclusion is the preferred treatment.",
"   </p>",
"   <p>",
"    CT, ventilation-perfusion, and angiographic imaging studies performed during ACS episodes show filling defects in pulmonary arteries, often in the area of an infiltrate resulting from sickle cell vasoocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Autopsy studies confirm that the pulmonary artery filling defects in the setting of ACS episodes are often comprised of bone marrow elements [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/14,36\">",
"     14,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms and signs consistent with a vasoocclusive pain crisis (ie, systemic pain and increased hemolysis) are more suggestive of ACS as a causative etiology than a pulmonary embolus. Although a patient with a pulmonary embolus may present with shortness of breath and chest pain similar to ACS, pulmonary emboli will typically have a chest radiograph negative for new radiodensities. However, some cases of ACS may initially present without evidence of a lung infiltrate, with subsequent ventilation-perfusion scans yielding evidence of widespread",
"    <em>",
"     in situ",
"    </em>",
"    thrombi within the lungs consistent with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence in favor of the presence of pulmonary emboli includes deep venous thrombosis on ultrasound imaging of the lower extremities or a recent period of immobility or surgery. If a pulmonary artery filling defect is seen on imaging studies, regardless of suspected etiology, our practice is to initiate anticoagulation unless otherwise contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239977\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coronary syndrome secondary to a ruptured atherosclerotic plaque in a coronary artery is uncommon in adults with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Autopsy studies performed in adults with SCD show little evidence of coronary artery disease, likely due to lower total cholesterol and low density lipoprotein cholesterol levels in adults with SCD compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/43-49\">",
"     43-49",
"    </a>",
"    ]. However, myocardial damage can occur during episodes of pain and ACS secondary to vasoocclusion or bone marrow or fat emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Bone marrow emboli obstructing the coronary arteries have been found in some patients at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting a vasoocclusive pain episode, myocardial damage can be an indicator of acute multi-organ failure syndrome and transfusion therapy should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/19,28\">",
"     19,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13239984\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia without ACS cannot be reliably distinguished from pneumonia with ACS on clinical grounds [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Therefore, empiric antibiotic therapy for community acquired pneumonia, including coverage for atypical bacteria, is a mainstay of ACS treatment. (See",
"    <a class=\"local\" href=\"#H25011428\">",
"     'Antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955336\">",
"    <span class=\"h1\">",
"     BIOMARKERS FOR ACS IN ADULTS WITH SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secretory phospholipase A2 (sPLA2) liberates free fatty acids from phospholipids. These free fatty acids are thought to contribute to the inflammation and tissue damage of ACS episodes associated with fat emboli. Among children with SCD and ACS, sPLA2 levels are 100-fold increased over normal controls and 35-fold greater than patients with SCD at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/54\">",
"     54",
"    </a>",
"    ]. Of interest, in patients without SCD, sPLA2 levels have been found to be predictive of risk for developing fat emboli syndrome following surgery.",
"   </p>",
"   <p>",
"    Investigators examined the ability of sPLA2 levels to predict ACS episodes in children admitted with a painful crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/55\">",
"     55",
"    </a>",
"    ]. Twenty-one children with SCD (ages 1 to 20 years, mean 11 years) were admitted to the hospital for a pain episode, and six went on to develop ACS. Although sPLA2 levels were elevated in all six children (100 percent sensitivity), the specificity was only 67 percent. Adding fever or respiratory symptoms improved the specificity to 87 percent, without affecting sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955343\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ACS for adults with SCD can be broadly categorized as acute and preventative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18682236\">",
"    <span class=\"h2\">",
"     Overall approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians taking care of adults with sickle cell disease (SCD), as contrasted with those taking care of children with SCD, often fail to recognize the gradations of severity of acute chest syndrome (ACS). Although ACS may present initially as severe episodes in some patients, in others it may evolve during the first 48 to 72 hours following a pain episode.",
"   </p>",
"   <p>",
"    In such cases, initial findings may include chest pain with minimal or no",
"    <span class=\"nowrap\">",
"     hypoxia/hypoxemia",
"    </span>",
"    (eg, &lt;4",
"    <span class=\"nowrap\">",
"     liters/min",
"    </span>",
"    of oxygen via nasal cannula required to maintain oxygen saturation &ge;92 percent, oxygen pressure &ge;70 mmHg) and an infiltrate involving one lobe or no infiltrates at all.",
"   </p>",
"   <p>",
"    Accordingly, suspicion for the presence of and development of ACS during a pain episode should be high, and appropriate therapy, as discussed below, instituted immediately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955350\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute therapy of ACS includes the following components, which are described in greater detail in the following sections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adequate and immediate pain control",
"     </li>",
"     <li>",
"      Fluid management to prevent hypovolemia",
"     </li>",
"     <li>",
"      Supplementary oxygen and incentive spirometry",
"     </li>",
"     <li>",
"      Blood transfusion",
"     </li>",
"     <li>",
"      Antibiotics",
"     </li>",
"     <li>",
"      Venous thromboembolism (VTE) prophylaxis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18682244\">",
"    <span class=\"h3\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain control with parenteral opioids typically delivered by patient-controlled analgesia is necessary during ACS episodes in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=see_link\">",
"     \"Acute pain management in adults with sickle cell disease\"",
"    </a>",
"    .) Careful monitoring is necessary to avoid over-sedation, which can lead to depressed respiratory rate, poor inspiration, hypoxemia, and worsening vasoocclusion and ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18682274\">",
"    <span class=\"h3\">",
"     Fluids management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluids should be administered to prevent hypovolemia. The typical regimen is 1.5 times maintenance fluids of D5 in one-half normal saline for the first 24 to 48 hours. Thereafter, the rate can be decreased as the patient begins to drink fluids. Fluid balance should be monitored frequently to avoid fluid overload and pulmonary edema, which can worsen the ACS process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=see_link&amp;anchor=H27#H27\">",
"     \"Acute pain management in adults with sickle cell disease\", section on 'Volume status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25011400\">",
"    <span class=\"h3\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized trials to determine the optimal ACS therapy in adults with SCD; however, the mainstay of acute treatment is transfusion therapy. Per expert recommendations, the need for transfusion and the modality of transfusion (simple versus exchange transfusion) depend upon the severity of the ACS episode [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. Mild episodes require no transfusion, moderate episodes require simple or exchange transfusion, and severe episodes require exchange transfusion.",
"   </p>",
"   <p>",
"    There are advantages to exchange transfusion compared with simple transfusion that make exchange transfusion the preferred method in severely affected adults. Exchange transfusion performed by erythrocytapheresis allows for the rapid transfusion of large amounts of blood (eg, 6 to 8 units of packed red blood cells for a typical adult), effectively decreasing hemoglobin S percentage while avoiding the hyperviscosity that may occur when hemoglobin levels are raised above 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unlikely that a randomized trial will ever be done to demonstrate that an exchange transfusion performed by erythrocytapheresis is superior to simple transfusion because of a lack of equipoise among clinicians who provide care to patients with ACS. However, it is our practice to perform an exchange transfusion by erythrocytapheresis for adults with moderate to severe ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of erythrocytapheresis may depend upon local resources. Knowledge of the capacity to perform the procedure at one&rsquo;s local site is an important factor to consider, given the potential for rapid onset of respiratory failure and the requirement to treat promptly. In settings where an exchange transfusion, either erythrocytapheresis or manual, is not available, we recommend consideration of transfer to a facility that has this capacity.",
"   </p>",
"   <p>",
"    When erythrocytapheresis is performed, end-hemoglobin S percentage and hemoglobin should be 30 percent and 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell units for transfusion should be negative for sickle cell trait (Sickledex negative) and phenotypically matched for C, E, and Kell antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Such extended matching reduces the rate of alloimmunization in patients with SCD from 3 to 0.5 percent per unit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the management of sickle cell disease\", section on 'Alloimmunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our practice is to intervene in cases of mild or developing ACS with simple transfusion to increase the hemoglobin up to 10",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    If instituted promptly, it is our experience that many episodes of moderate to severe ACS events can be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For moderate to severe episodes involving &gt;1 lobe and with an oxygen requirement &ge;4 liters nasal cannula to maintain PaO2 &gt;70 mmHg (approximately corresponding to an oxygen saturation of 92 percent) or signs of clinical deterioration, our practice is to perform an exchange transfusion. The preferred modality of exchange transfusion is erythrocytapheresis to achieve a hemoglobin S percentage &lt;30 percent, and we target an end-hemoglobin of 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    If an exchange transfusion cannot be performed in a timely manner, we recommend simple transfusions to temporize the progression of ACS. Usually, cases of moderate to severe ACS are managed in the intensive care unit.",
"   </p>",
"   <p>",
"    Regardless of ACS severity, if hemoglobin is &lt;5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    simple transfusion should be delivered to increase hemoglobin to 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25011407\">",
"    <span class=\"h3\">",
"     Bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trial has evaluated the use of bronchodilators in the treatment of ACS. Despite the lack of high quality evidence, bronchodilators are commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/23\">",
"     23",
"    </a>",
"    ]. In the NACSG, bronchodilators were administered to 61 percent of participants during an episode of ACS; clinical improvement as defined by a &gt;15 percent increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    was reported in 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ]. As wheezing occurs less commonly during ACS episodes in adults compared with children with SCD (16 versus 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ]) bronchodilators may benefit fewer adults.",
"   </p>",
"   <p>",
"    Potentially, bronchodilators are more effective during an ACS episode in adults with asthma. Use of bronchodilators should also be considered in the setting of progressive respiratory distress occurring in ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25011428\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although infections are a less common cause of ACS in adults than in children with SCD, empiric antibiotics should be started promptly. The most common organisms are atypical bacteria (",
"    <em>",
"     Chlamydia",
"    </em>",
"    and",
"    <em>",
"     Mycoplasma",
"    </em>",
"    ) along with",
"    <em>",
"     Streptococcus pneumonia",
"    </em>",
"    and",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    , and therefore a third generation cephalosporin along with a macrolide, or a fourth generation fluoroquinolone are typical regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, we administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    1 to 2 grams IV every eight hours plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    500 mg orally or IV once daily for seven days or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    400 mg orally or IV for seven days. The antibiotic regimen can be tailored based on culture results. Notably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    should be used with caution as drug-induced immune hemolysis has been associated with ceftriaxone in children with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The same mechanism of hemolysis may be associated with other cephalosporins, including cefotaxime; although other than ceftriaxone, no case report of drug-induced hemolysis has been identified, quite possibly because ceftriaxone is the most commonly used cephalosporin for treating individuals with SCD and fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3817737\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucocorticoids is not standard practice for the management of ACS in adults with SCD. Studies of these agents for the treatment of ACS have been performed in children with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], including a randomized controlled trial of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/62\">",
"     62",
"    </a>",
"    ]. Although length of hospital stay was decreased in children receiving dexamethasone, a high rate of painful episodes occurred following their discontinuation. The phenomenon of rebound vasoocclusion after a course of steroids has been confirmed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25011414\">",
"    <span class=\"h3\">",
"     Incentive spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incentive spirometry has been examined as a measure to prevent ACS episodes in children with SCD who were admitted to the hospital for a painful crisis. Performing incentive spirometry using 10 maximal breaths every two hours while awake was associated with a significantly reduced rate of developing ACS versus no incentive spirometry (5 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/65\">",
"     65",
"    </a>",
"    ]. There have been no studies to determine the efficacy of incentive spirometry to prevent worsening of ACS. However, standard practice includes ongoing use of incentive spirometry when a patient is admitted to the hospital and develops ACS.",
"   </p>",
"   <p>",
"    Incentive spirometry should be encouraged with 10 maximal breaths every two hours while awake to prevent ACS during vaso-occlusive pain episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25011421\">",
"    <span class=\"h3\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen needs to be delivered to adults with ACS who have low oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) or low oxygen partial pressure (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ). When oxygen saturation is calculated based on measurements from pulse oximetry or an arterial blood gas, there can be discordance with oxygen pressure, which is measured directly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/66\">",
"     66",
"    </a>",
"    ]. Calculated oxygen saturation is based on a normal oxyhemoglobin dissociation curve, while patients with SCD have a right-shifted curve due to the presence of hemoglobin S and fetal hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/67\">",
"     67",
"    </a>",
"    ]. Pulse oximetry-derived measurements of oxygen saturation typically underestimate oxygen pressure, whereas arterial blood gas calculations may overestimate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vasoconstriction, hypotension, and hypothermia can also affect pulse oximetry values, since the basis for these measurements is light absorbed from fingertip blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/68\">",
"     68",
"    </a>",
"    ]. Co-oximetry measures different types of hemoglobin and provides the most accurate measure of oxygen saturation in patients with SCD. Most arterial blood gas analyses in the United States use co-oximetry to measure oxygen saturation. If the presence of hypoxemia is critical to the management of the patient with SCD, an arterial blood gas is required to directly measure oxygen pressure and saturation by co-oximetry.",
"   </p>",
"   <p>",
"    We recommend the delivery of oxygen when oxygen saturation (Sa0",
"    <sub>",
"     2",
"    </sub>",
"    ) is &lt;92 percent or oxygen pressure (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) is &lt;70 mmHg. Oxygen saturation levels &lt;92 percent calculated from pulse oximetry should be further evaluated with an arterial blood gas sample. If the patient is known to have a steady state oxygen saturation &lt;92 percent, a comparison to the baseline value may be helpful. In this case, decreases of &ge;3 percent should be evaluated with an arterial blood gas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17232285\">",
"    <span class=\"h3\">",
"     VTE prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACS is an acute medical illness that predisposes patients to venous thromboembolic (VTE) events. All adult patients with ACS should receive VTE prophylaxis with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , unfractionated heparin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    . Our preference is to administer a once daily prophylactic dose of low molecular weight heparin or fondaparinux. In contrast, we do not use routine thromboprophylaxis for VTE in hospitalized children with SCD (ie, those less than 21 years). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25011435\">",
"    <span class=\"h3\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the invasiveness of bronchoscopy, this procedure is reserved for atypical cases or cases refractory to conventional therapy. Although bronchoscopy with bronchoalveolar lavage was used in studies to evaluate for evidence of fat emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/6,17,20\">",
"     6,17,20",
"    </a>",
"    ], this procedure is not part of standard care. Since transfusion therapy is the mainstay of ACS treatment regardless of the underlying etiology, the risks of performing routine bronchoscopy outweigh the added diagnostic value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955357\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modalities that have been employed to prevent future episodes of ACS have included chronic transfusion therapy, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , and hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3190023\">",
"    <span class=\"h3\">",
"     Chronic transfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scheduled transfusion therapy has been performed to reduce the incidence of ACS episodes in adults with SCD; however, there have been no prospective trials to support this practice. However, in children with SCD who were chronically transfused for secondary stroke prophylaxis as part of the Stroke Prevention Trial, the incidence of ACS was reduced from 15.8 events per 100 years to 4.8 events per 100 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our practice is to initiate chronic transfusion therapy only in adults who have had two or more episodes of moderate to very severe ACS in the past 24 months despite maximal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    therapy. We perform exchange transfusions either manually or via erythrocytapheresis every four to six weeks to maintain a hemoglobin S percentage &lt;50 percent. Chronic transfusion therapy is continued for one to two years. Thereafter, the decision to continue transfusion therapy is based on a re-examination of the risk-to-benefit ratio accounting for factors such as iron overload, alloimmunization, and recent clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18682356\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is the only treatment that has been shown to decrease the incidence rate of ACS episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/72\">",
"     72",
"    </a>",
"    ]. In a randomized trial in 299 adults with SCD who were treated with hydroxyurea or placebo for an average of 21 months, the incidence rate of ACS episodes was 50 percent lower in the hydroxyurea group compared with those receiving placebo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H609480611#H609480611\">",
"     \"Specific therapies for sickle cell disease\", section on 'Studies in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    titrated up to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or an absolute neutrophil count of",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    should be administered to all adults with a history of ACS regardless of genotype, unless contraindicated (ie, renal failure). Furthermore, hydroxyurea therapy should be considered for all adults with HbSS who are not on a chronic transfusion program based on data showing improved mortality with hydroxyurea use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/54/9066/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18682370\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cell transplant, while curative, is not part of standard practice for",
"    <strong>",
"     adults",
"    </strong>",
"    with SCD due to high toxicity associated with myeloablative regimens. However, a non-myeloablative conditioning regimen in adults with SCD is well-tolerated, achieves stable, mixed donor-recipient chimerism, and improves clinical SCD parameters, including episodes of acute chest syndrome. This issue, and its effect on recurrent episodes of ACS, is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link&amp;anchor=H31285832#H31285832\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\", section on 'Survival and engraftment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955364\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute chest syndrome (ACS) is a leading cause of death for patients with sickle cell disease (SCD). It is defined as a new radiodensity on chest radiograph accompanied by fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory symptoms. ACS requires prompt management to prevent clinical deterioration and death.",
"     </li>",
"     <li>",
"      Required criteria for making the diagnosis of ACS and assessing its severity are given in the text. (See",
"      <a class=\"local\" href=\"#H13239723\">",
"       'Diagnosis of ACS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major disorders to be distinguished from ACS include pulmonary embolus, acute coronary syndrome, and pneumonia. Since pneumonia without ACS cannot be reliably distinguished from pneumonia with ACS on clinical grounds, empiric antibiotic therapy for community acquired pneumonia, including coverage for atypical bacteria, is a mainstay of ACS treatment. (See",
"      <a class=\"local\" href=\"#H955322\">",
"       'Other etiologies of ACS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The supportive management of an episode of ACS requires a number of active interventions, including adequate pain control and fluid management, use of bronchodilators when wheezing is present, incentive spirometry to prevent the development of pulmonary atelectasis, and use of supplemental oxygen. (See",
"      <a class=\"local\" href=\"#H955343\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific therapies for ACS include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For mild episodes of ACS we suggest the use of simple transfusion, while for moderate to severe ACS we suggest the use of exchange transfusion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The final target hemoglobin should be no higher than 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Regardless of ACS severity, we recommend simple transfusion in all patients with a hemoglobin &lt;5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      as a hemoglobin S percentage close to 30 percent can be achieved by simple transfusion alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25011400\">",
"       'Transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As pneumonia cannot be reliably distinguished from ACS, we recommend prompt initiation of antibiotics in all patients with ACS (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our preference is to employ a third generation cephalosporin and a macrolide or a fourth generation fluoroquinolone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As ACS is an acute medical condition, we recommend thromboprophylaxis in all adults with SCD admitted to the hospital for ACS (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our preference is to administer a once daily prophylactic dose of low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=see_link&amp;anchor=H37#H37\">",
"       \"Prevention of venous thromboembolic disease in medical patients\", section on 'Assignment of risk group'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For prevention of ACS recurrence as well as overall reduction in mortality, we recommend that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      be administered to all adults with a history of ACS unless otherwise contraindicated (ie, renal failure) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18682356\">",
"       'Hydroxyurea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have two or more episodes of moderate to very severe ACS episodes in a 24-month period despite maximal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      therapy, we suggest a chronic transfusion program to maintain a hemoglobin S percentage &lt;50 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15928844\">",
"       'ACS severity index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefits and risks of hematopoietic cell transplantation, and its effect on reducing the incidence of recurrent ACS are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link&amp;anchor=H21142822#H21142822\">",
"       \"Hematopoietic cell transplantation in sickle cell disease\", section on 'Indications for HCT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/1\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/2\">",
"      Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed) 1982; 285:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/3\">",
"      Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/4\">",
"      Dang NC, Johnson C, Eslami-Farsani M, Haywood LJ. Bone marrow embolism in sickle cell disease: a review. Am J Hematol 2005; 79:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/5\">",
"      Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/6\">",
"      Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/7\">",
"      Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997; 89:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/8\">",
"      Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/9\">",
"      Maitre B, Habibi A, Roudot-Thoraval F, et al. Acute chest syndrome in adults with sickle cell disease. Chest 2000; 117:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/10\">",
"      Cohen RT, DeBaun MR, Blinder MA, et al. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood 2010; 115:3852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/11\">",
"      Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988; 67:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/12\">",
"      Field JJ, Burdick MD, DeBaun MR, et al. The role of fibrocytes in sickle cell lung disease. PLoS One 2012; 7:e33702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/13\">",
"      Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/14\">",
"      Zaidi Y, Sivakumaran M, Graham C, Hutchinson RM. Fatal bone marrow embolism in a patient with sickle cell beta + thalassaemia. J Clin Pathol 1996; 49:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/15\">",
"      Scully RE, Mark EJ, McNeely WF, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1997. A 74-year-old man with progressive cough, dyspnea, and pleural thickening. N Engl J Med 1997; 336:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/16\">",
"      Hutchinson RM, Merrick MV, White JM. Fat embolism in sickle cell disease. J Clin Pathol 1973; 26:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/17\">",
"      Lechapt E, Habibi A, Bachir D, et al. Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2003; 168:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/18\">",
"      Rayburg M, Kalinyak KA, Towbin AJ, et al. Fatal bone marrow embolism in a child with hemoglobin SE disease. Am J Hematol 2010; 85:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/19\">",
"      Ataga KI, Orringer EP. Bone marrow necrosis in sickle cell disease: a description of three cases and a review of the literature. Am J Med Sci 2000; 320:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/20\">",
"      Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/21\">",
"      Shapiro MP, Hayes JA. Fat embolism in sickle cell disease. Report of a case with brief review of the literature. Arch Intern Med 1984; 144:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/22\">",
"      Garza JA. Massive fat and necrotic bone marrow embolization in a previously undiagnosed patient with sickle cell disease. Am J Forensic Med Pathol 1990; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/23\">",
"      Melton CW, Haynes J Jr. Sickle acute lung injury: role of prevention and early aggressive intervention strategies on outcome. Clin Chest Med 2006; 27:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/24\">",
"      Kaplan RP, Grant JN, Kaufman AJ. Dermatologic features of the fat embolism syndrome. Cutis 1986; 38:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/25\">",
"      Lowenthal EA, Wells A, Emanuel PD, et al. Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol 1996; 51:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/26\">",
"      Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/27\">",
"      PELTIER LF. Fat embolism. III. The toxic properties of neutral fat and free fatty acids. Surgery 1956; 40:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/28\">",
"      Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994; 96:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/29\">",
"      Dean D, Neumayr L, Kelly DM, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol 2003; 25:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/30\">",
"      Neumayr L, Lennette E, Kelly D, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics 2003; 112:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/31\">",
"      Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007; 28:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/32\">",
"      Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/33\">",
"      Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003; 123:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/34\">",
"      Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002; 33:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/35\">",
"      Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med 1982; 73:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/36\">",
"      Adedeji MO, Cespedes J, Allen K, et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001; 125:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/37\">",
"      Sutton LL, Castro O, Cross DJ, et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994; 74:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/38\">",
"      Charache S, Scott JC, Charache P. \"Acute chest syndrome\" in adults with sickle cell anemia. Microbiology, treatment, and prevention. Arch Intern Med 1979; 139:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/39\">",
"      Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999; 94:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/40\">",
"      Davies SC, Luce PJ, Win AA, et al. Acute chest syndrome in sickle-cell disease. Lancet 1984; 1:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/41\">",
"      Bhalla M, Abboud MR, McLoud TC, et al. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology 1993; 187:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/42\">",
"      Feldman L, Gross R, Garon J, et al. Sickle cell patient with an acute chest syndrome and a negative chest X-ray: potential role of the ventilation and perfusion (V/Q) lung scan. Am J Hematol 2003; 74:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/43\">",
"      Buchowski MS, Swift LL, Akohoue SA, et al. Defects in postabsorptive plasma homeostasis of fatty acids in sickle cell disease. JPEN J Parenter Enteral Nutr 2007; 31:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/44\">",
"      el-Hazmi MA, Jabbar FA, Warsy AS. Cholesterol and triglyceride level in patients with sickle cell anaemia. Scand J Clin Lab Invest 1987; 47:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/45\">",
"      Westerman MP, Diloy-Puray M, Streczyn M. Membrane components in the red cells of patients with sickle cell anemia. Relationship to cell aging and to irreversibility of sickling. Biochim Biophys Acta 1979; 557:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/46\">",
"      Stone WL, Payne PH, Adebonojo FO. Plasma-vitamin E and low plasma lipoprotein levels in sickle cell anemia patients. J Assoc Acad Minor Phys 1990; 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/47\">",
"      Sasaki J, Waterman MR, Buchanan GR, Cottam GL. Plasma and erythrocyte lipids in sickle cell anaemia. Clin Lab Haematol 1983; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/48\">",
"      Marzouki ZM, Khoja SM. Plasma and red blood cells membrane lipid concentration of sickle cell disease patients. Saudi Med J 2003; 24:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/49\">",
"      el-Hazmi MA, Warsy AS, al-Swailem A, et al. Red cell genetic disorders and plasma lipids. J Trop Pediatr 1995; 41:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/50\">",
"      Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 2010; 85:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/51\">",
"      Haywood LJ. Cardiovascular function and dysfunction in sickle cell anemia. J Natl Med Assoc 2009; 101:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/52\">",
"      Martin CR, Cobb C, Tatter D, et al. Acute myocardial infarction in sickle cell anemia. Arch Intern Med 1983; 143:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/53\">",
"      Norris S, Johnson CS, Haywood LJ. Sickle cell anemia: does myocardial ischemia occur during crisis? J Natl Med Assoc 1991; 83:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/54\">",
"      Styles LA, Schalkwijk CG, Aarsman AJ, et al. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996; 87:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/55\">",
"      Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood 2000; 96:3276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/56\">",
"      Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009; 114:5117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/57\">",
"      Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/58\">",
"      Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/59\">",
"      Reagan MM, DeBaun MR, Frei-Jones MJ. Multi-modal intervention for the inpatient management of sickle cell pain significantly decreases the rate of acute chest syndrome. Pediatr Blood Cancer 2011; 56:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/60\">",
"      Goyal M, Donoghue A, Schwab S, et al. Severe hemolytic crisis after ceftriaxone administration. Pediatr Emerg Care 2011; 27:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/61\">",
"      Schuettpelz LG, Behrens D, Goldsmith MI, Druley TE. Severe ceftriaxone-induced hemolysis complicated by diffuse cerebral ischemia in a child with sickle cell disease. J Pediatr Hematol Oncol 2009; 31:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/62\">",
"      Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/63\">",
"      Strouse JJ, Takemoto CM, Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008; 50:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/64\">",
"      Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/65\">",
"      Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/66\">",
"      Weston Smith SG, Glass UH, Acharya J, Pearson TC. Pulse oximetry in sickle cell disease. Clin Lab Haematol 1989; 11:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/67\">",
"      Rackoff WR, Kunkel N, Silber JH, et al. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood 1993; 81:3422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/68\">",
"      Kress JP, Pohlman AS, Hall JB. Determination of hemoglobin saturation in patients with acute sickle chest syndrome: a comparison of arterial blood gases and pulse oximetry. Chest 1999; 115:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/69\">",
"      Fitzgerald RK, Johnson A. Pulse oximetry in sickle cell anemia. Crit Care Med 2001; 29:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/70\">",
"      Mullin JE, Cooper B, Seicean S, et al. Variability of pulse oximetry measurement over 1 year in children with sickle cell disease depends on initial oxygen saturation measurement. Pediatr Blood Cancer 2010; 54:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/71\">",
"      Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/72\">",
"      Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/73\">",
"      Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/74\">",
"      Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/54/9066/abstract/75\">",
"      Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16353 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C815FD8784-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9066=[""].join("\n");
var outline_f8_54_9066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H955364\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955280\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13239481\">",
"      DIFFERENCES BETWEEN ACS IN CHILDREN AND ADULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955287\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239503\">",
"      Repeated episodes of ACS and interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3817698\">",
"      Repeated episodes of ACS and pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955301\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955308\">",
"      BONE MARROW AND FAT EMBOLI AS A CAUSE OF ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239548\">",
"      Clinical and laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H955315\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13239555\">",
"      - Association with the multi-organ failure syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955322\">",
"      OTHER ETIOLOGIES OF ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239577\">",
"      Infection and asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239584\">",
"      Compromised ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239591\">",
"      Pulmonary thrombi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13239723\">",
"      DIAGNOSIS OF ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15928837\">",
"      Diagnostic criteria for ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15928844\">",
"      ACS severity index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15928852\">",
"      - Mild ACS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15928867\">",
"      - Moderate ACS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15928882\">",
"      - Severe ACS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15928897\">",
"      - Very severe ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955329\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239970\">",
"      Pulmonary embolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239977\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13239984\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955336\">",
"      BIOMARKERS FOR ACS IN ADULTS WITH SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955343\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18682236\">",
"      Overall approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H955350\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18682244\">",
"      - Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18682274\">",
"      - Fluids management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25011400\">",
"      - Transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25011407\">",
"      - Bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25011428\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3817737\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25011414\">",
"      - Incentive spirometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25011421\">",
"      - Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17232285\">",
"      - VTE prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25011435\">",
"      - Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H955357\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3190023\">",
"      - Chronic transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18682356\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18682370\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955364\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=related_link\">",
"      Acute pain management in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_54_9067="Indications for abdominal paracentesis";
var content_f8_54_9067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for abdominal paracentesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        New onset ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospitalization of a patient with ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Clinical deterioration of an inpatient or outpatient with ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Abdominal tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Hepatic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Peripheral leukocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Deterioration in renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Acidosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9067=[""].join("\n");
var outline_f8_54_9067=null;
var title_f8_54_9068="Psychotherapies of choice";
var content_f8_54_9068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychotherapy for psychiatric disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Types of effective psychotherapy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bipolar disorder",
"       </td>",
"       <td>",
"        As an adjunct to pharmacotherapy: cognitive-behavioral therapy, individual and family psychoeducation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Borderline personality disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy, dialectical-behavioral therapy, and psychodynamic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulimia nervosa",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy and interpersonal therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized anxiety disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major depressive disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy, behavioral activation therapy, interpersonal psychotherapy, brief psychodynamic psychotherapy, mindfulness-based cognitive therapy, and if there is marital discord, marital therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obsessive compulsive disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panic disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phobic disorders",
"       </td>",
"       <td>",
"        Behavioral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posttraumatic stress disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizophrenia",
"       </td>",
"       <td>",
"        As an adjunct to pharmacotherapy: behavioral therapy, social skills training, and psychoeducation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance abuse disorder",
"       </td>",
"       <td>",
"        Cognitive-behavioral therapy, motivational interviewing,&nbsp;and 12-step treatments",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Broad categories of psychotherapy are listed in the table. The specific psychotherapy shown to be effective for an individual disorder has typically undergone extensive modification prior to clinical trials and may be referred to by a more specific name.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9068=[""].join("\n");
var outline_f8_54_9068=null;
var title_f8_54_9069="Post RT ambul rates scores";
var content_f8_54_9069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malignant epidural spinal cord compression: scoring system to predict outcomes post-radiotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Post-RT ambulatory rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Type of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast cancer",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prostate cancer",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myeloma/lymphoma",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-small-cell lung cancer",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small-cell lung cancer",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cancer of unknown primary",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal cell carcinoma",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colorectal cancer",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other tumors",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Interval from tumor diagnosis to MSCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;15 mo",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;15 mo",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Visceral metastases at the time of RT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yes",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Motor function before RT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ambulatory without aid",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ambulatory with aid",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not ambulatory",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paraplegic",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Time of developing motor deficits before RT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-7 days",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8-14 days",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;14 days",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RT: radiotherapy; MSCC: metastatic spinal cord compression.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rades D, Rudat V, Veninga T, et al. A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression. Int J Rad Oncol Biol Phys 2008; 72:905. Illustration used with the permission of Elsevier, Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9069=[""].join("\n");
var outline_f8_54_9069=null;
var title_f8_54_9070="Gemcitabine plus cisplatin regimen for NSCLC";
var content_f8_54_9070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gemcitabine plus cisplatin for non-small cell lung cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days, for a maximum of six cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gemcitabine",
"        </strong>",
"       </td>",
"       <td>",
"        1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV*",
"       </td>",
"       <td>",
"        Dilute in 100 mL normal saline (NS) (concentration no more than 40 mg/mL) and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Days 1 and 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Day 1: HIGH; Day 8: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended (risk of neutropenic fever is approximately 4 percent). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for preexisting baseline renal or liver dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [2]",
"        </sup>",
"        . A lower starting dose of gemcitabine may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Electrolytes, renal, and liver function weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Each cycle should not begin until the WBC count is greater than 3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 100,000 cells/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . Gemcitabine should be withheld on day 8 if the WBC count is less than 2000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets are less than 50,000 cells/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . This is consistent with the US FDA approved product information to hold gemcitabine for an ANC less than 500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets less than 50,000 cells/mm",
"        <sup>",
"         3[3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hemolytic-uremic syndrome (HUS):",
"        </strong>",
"        In clinical trials, HUS was reported in 0.25 percent of patients receiving gemcitabine. Consider diagnosis if the patient develops hemolysis and severe thrombocytopenia, with or without renal failure or central nervous system findings. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Severe non-hematologic toxicity:",
"        </strong>",
"        Gemcitabine and cisplatin should be withheld or doses decreased depending on clinical judgement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; WBC: white blood cell; ANC: absolute neutrophil count.",
"     <br/>",
"     * This dose of gemcitabine differs slightly from that originally published",
"     <sup>",
"      [2]",
"     </sup>",
"     but is used in the current ECOG protocol",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       National Institutes of Health Clinical Trials database. Eastern Cooperative Oncology Group protocol E1505. (Available online at www.clinicaltrials.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Scagliotti GV, et al. J Clin Oncol 2008; 26:3543.",
"      </li>",
"      <li>",
"       Gemzar (gemcitabine hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9070=[""].join("\n");
var outline_f8_54_9070=null;
var title_f8_54_9071="Adams forward bend test";
var content_f8_54_9071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adams forward bend test for scoliosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Adams forward bend test demonstrates the rotational component of scoliosis. It is performed by observing the patient from the back while he or she bends forward at the waist until the spine becomes parallel to the horizontal plane. The patient's feet should be together, knees straight ahead, and arms hanging free. Asymmetry of the upper thoracic, midthoracic, thoracolumbar, or lumbar region is noted. The drawing above depicts the right rib hump of thoracic scoliosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_54_9071=[""].join("\n");
var outline_f8_54_9071=null;
